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III Abstract 
Microglia are the resident immune cells of the central nervous system (CNS). They 
display a whole set of recognition receptors on their cell surface to sense intact or 
lesioned cells in the CNS. A subfamily of these receptors are sialic acid-binding 
immunoglobulin like lectins (Siglecs). Siglecs can either exert activatory or inhibitory 
signals. Siglec-E is a member of this receptor family and has an immunoreceptor 
tyrosine based inhibitory motif (ITIM) in the cytoplasmic tail to suppress activatory 
microglial signals.  
To study Siglec-E transcription and expression profile ex vivo, primary and stem cell-
derived microglia were used. Via RT-PCR and flow cytometry it was shown that 
Siglec-E is expressed on microglia and was up-regulated following IFN-γ treatment. 
To study the functional role of Siglec-E, lentiviral knock-down and overexpression of 
Siglec-E was performed. Lentiviral overexpression of Siglec-E decreased whereas 
knock-down increased the phagocytosis rate of neural debris and its associated 
reactive oxygen burst. The extracellular domain of Siglec-E linked to the Fc-part of 
immunoglobulin bound to the sialic acid residues of the neuronal glycocalyx. 
Therefore, primary hippocampal neurons were co-cultured with the modified 
microglia. Overexpression and knock-down of Siglec-E led to an increase and 
decrease in relative neurite length, respectively. The neuroprotective effect of 
Siglec-E was abrogated after removal of the sialic acid residues on the neuronal 
glycocalyx. Treatment with the anti-oxidant Trolox abolished the neurotoxic effect of 
the Siglec-E knock-down on neurite length.  
In summary, our data suggest an immunomodulatory function of Siglec-E on 
microglia, which leads to a neuroprotective phenotype by decreasing the production 
of reactive oxygen species and a reduced phagocytosis rate of neural debris. 
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1.1 Microglia 
1.1.1 History of microglia 
The first scientist who described cells of the CNS, which did not show the 
appearance of neurons, in 1846 was the German pathologist Rudolf Virchow (1821 – 
1902). He assumed that these cells fulfil the function of a connective tissue of the 
brain and ascribed them two functions: to support the neurons and to participate in 
the repair of the tissue. Nowadays it is known that two major cell types populate the 
CNS: nerve cells and glial cells. Glial cells consist of astrocytes, oligodendrocytes 
and microglia. The discrimination of microglia against astrocytes and 
oligodendrocytes as a separate cell type was discovered by Rio-Hortega in the early 
20th century by his silver carbonate staining method (Figure 1.1) (del Rio-Hortega 
and Penfield 1927). Rio-Hortega described those cells as a cell population differing 
from other glial cell types like astrocytes and neurons and was the first scientist 
postulating the concept of the mesodermal origin of microglial cells (del Rio-Hortega 
1932).  
 
Figure 1.1: Silver staining of microglial cells by del Rio-Hortega (del Rio-Hortega 1919). With his 
silver carbonate staining del Rio-Hortega was the first scientist who distinguished between glial cell 
types. 
 
 
 
1. Introduction 2 
 
1.1.2 Origin of microglia 
The recent consensus is that microglia emanate from myeloid cells. Alliot and 
colleagues were able to show microglial progenitors positive for the 
macrophage/microglia markers macrophage-1 antigen (Mac-1), F4/80 and fragment 
crystallisable receptor (Fc-R) at the proto-somitic stage at embryonic day 8 (E8) in 
the neural folds where the embryo consists of 4-8 somites (Alliot et al. 1991).  
A more recent study provides additional evidence that microglia derive from myeloid 
progenitors that arise before E8 from the yolk sac. Furthermore perinatal circulating 
hematopoietic precursors seem not to play a role in the homeostasis of microglia and 
invasion of bone marrow-derived cells only occurs upon injury (Ginhoux et al. 2010). 
Kierdorf and collegues were able to demonstrate that microglia emerge from 
erythromyeloid precursors from the yolk sac which can be identified at 9 days post 
conception as cluster of differentiation (CD) 45- c-kit+ cells. The further development 
seems to be dependent on the transcription factors Pu.1 and Irf8 (Kierdorf et al. 
2013).  
 
1.1.3 Morphology and function of microglia 
Microglia constitute 5-20 % of the adult brain cell population depending on the 
species; in the adult mouse brain approximately 10 % of the cells are microglia 
(Lawson et al. 1990). The whole mouse brain harbours about 3.5 x 106 microglia. Of 
the glial cell population they represent about 20 %. Compared to the other glia they 
are the smallest. 
Microglia are distributed throughout the brain and spinal cord and are more abundant 
in the grey compared to the white matter. Particularly dense populated areas are the 
hippocampus, basal ganglia, substantia nigra and parts of the telencephalon. 
Microglia are found as well in greater numbers in the cerebral cortex, thalamus and 
hypothalamus (Lawson et al. 1990). They form the first line of defence in the CNS. 
Resting ramified microglia of the adult brain have only little or no visible cytoplasm. In 
their cytoplasm they have vacuoles suggesting their phagocytic activity and diverse 
finely-branched processes that have additional protrusions (Ransohoff and Perry 
2009). Microglia concentrate in perivascular and perineuronal positions. On their cell 
surface they only express few surface markers of the monocyte-macrophage line, 
e.g. fragment crystallisable (Fc) and complement receptor whereas amoeboid 
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microglia have surface markers of the monocyte-macrophage lineage and an 
abundant cytoplasm (Barron 1995).  
In vivo two-photon studies showed that microglia occur in two major forms but the 
metamorphosis between these conformational extremes is fluent. The “ramified” 
microglia have highly motile processes and branches (Figure 1.2). By constant 
withdrawal and de novo formation of their processes they are able to scan their 
microenvironment without movement of the cell body. Thereby, they do not disturb 
any fine-wired neuronal structures. Their duty is the homeostatic surveillance 
(Davalos et al. 2005; Nimmerjahn et al. 2005). Resting ramified microglia receive 
inhibitory signals via for example their CX3CR1 receptor. The ligand CX3 chemokine 
ligand 1 (CX3CL1) is secreted by neurons in the CNS (Cardona et al. 2006). Vice 
versa microglia produce immunosuppressive factors like Interleukin (IL) 10 and 
transforming growth factor- (TGF-) as well as neurotrophic factors to support 
neuronal function and survival (Hanisch 2002; Ransohoff and Perry 2009).  
 
 
  
 
Figure 1.2: Different states of microglia. Resting microglia scan their environment and have a highly 
ramified structure. Upon activation they retract their processes and change to the amoeboid stage 
(modified from Perry et al., 2007). 
 
 
If the inhibitory CX3CR1 impulse is absent microglia become neurotoxic. Other 
stimuli can also trigger the activation of microglia such as the bacterial cell wall 
component lipopolysaccharide (LPS), viral ribonucleic acid (RNA) or the exposure to 
plasma proteins (Bechmann et al. 2007; Lehnardt 2010). Receptors recognizing 
these structures are of the Toll-like receptor (TLR) family or complement receptor 
MAC-1 triggered by opsonised bacteria (Stevens et al. 2007). Microglia express TLR 
1-9. Their activation leads to increased secretion of Interferon (IFN)-, IFN-, IL-1 
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and tumour necrosis factor (TNF)- as well as reactive oxygen species (ROS) and 
nitric oxide (NO). After activation microglia regress their processes and undergo a 
metamorphosis to the so-called “amoeboid” state. The expression of specific surface 
receptors is activated and they become motile. Once activated, microglial cells are 
enabled to phagocyte and to present antigens to circulating T cells (Chan et al. 2007; 
Lehnardt 2010). The reorientation can occur in minutes to seconds (Hanisch and 
Kettenmann 2007).  
Microglia eliminate cellular debris and redundant cells, which underwent apoptosis, 
without inducing inflammation. Find-me signals like ATP and UDP on damaged 
neurons enable the movement of microglia via the receptor P2Y6 (Koizumi et al. 
2007). Scavenger receptors perceive the translocation of phosphatidylserine from the 
inner leaflet onto the outer leaflet of the plasma membrane. The translocation leads 
to the recognition of an apoptotic cell (Ravichandran 2003; Ravichandran and Lorenz 
2007). In the end this process triggers the removal of dying cells or their debris. 
 
1.2 ITIM receptors 
 
1.2.1 Microglial carbohydrate receptors in neuroinflammation 
Microglia have different sets of receptors on their surface to fulfil their duties in the 
CNS. Additionally to the before mentioned TLRs, complement, cytokine and 
chemokine receptors microglia express carbohydrate-binding receptors on their 
surface. One family of these carbohydrate-binding receptors are the lectins, which 
can be further subdivided into three different classes: galectins, selectins and Siglecs 
(Schnaar 2004). Siglecs are carbohydrate receptors signalling via either an 
immunoreceptor tyrosine-based activation motif (ITAM) or an immunoreceptor 
tyrosine-based inhibition motif (ITIM). 
 
1.2.2 Definition and function of ITIM receptors 
The first ITIM was identified in the cytoplasmic domain of the receptor FcRIIB (Van 
Den Herik-Oudijk et al. 1994). ITIMs can be traced back to relatively primitive 
metazoa. Genes encoding ITIM-containing molecules belong to the immunoglobulin 
superfamily (IgSF) or the C-type lectin family. They are derived from a common set of 
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ancestor genes having expanded and diverged from fish to mammals (Daeron et al. 
2008). 
Vivier and colleagues defined ITIMs as short sequences harbouring a tyrosine (Y) 
which is followed by a hydrophobic residue (isoleucine (I), valine (V) or leucine (L)) at 
position Y+3 and preceded by a less conserved hydrophobic residue at position Y-2 
(Vivier and Daeron 1997). 
ITIM-containing molecules are involved in the control of a large spectrum of biological 
processes, mostly but not exclusively related to immunity. They act on several cell 
types such as T cells (Nagaishi et al. 2006), macrophages (Takizawa and Manz 
2007) and platelets (Cicmil et al. 2002; Rathore et al. 2003). Only recently it was 
shown that they participate in the promotion of proliferation (Kono et al. 2008) as well 
as apoptosis of cancer cells (Voisin et al. 2008). 
 
1.2.3 Signalling pathway 
ITIMs are the counterpart to activatory ITAM motifs. ITAM receptors are 
phosphorylated at their tyrosine residues by members of the Src kinase family (SKF) 
and then become a binding site for Syk protein kinases. When co-aggregated with an 
ITAM receptor ITIMs become phosphorylated by a tyrosine kinase of the Src-family, 
which enables them to recruit phosphatases, either Src homology 2 domain-
containing inositol polyphosphate 5´phosphatase (SHIP) or more common the Src 
homology 2 domain-containing protein tyrosine phosphatases (SHP)-1 and SHP-2. 
They are recruited via the binding of their SH2 domain(s) to the phosphorylated ITIM. 
The activated SHP1 then dephosphorylates intracellular signalling intermediates 
leading to the termination of an activatory signal generated by an ITAM receptor 
(Figure 1.3).  
The residue at position Y-2 determines the binding of SHP-1 and SHP-2 (Burshtyn et 
al. 1997; Olcese et al. 1996; Vely et al. 1997). For FcRIIB a loss-of-function study 
identified the leucine at position Y+2 as mandatory for recruitment of SHIP-1 and 
SHIP-2 in vitro and in vivo (Bruhns et al. 2000).  
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Figure 1.3: Signalling pathway of ITIM receptors. ITIM receptors inhibit the activatory signals of 
ITAM receptors (Linnartz et al., 2010). 
 
1.3 Siglecs 
 
1.3.1 Sialic acid 
The cell surface is covered by a broad variety of glycans that are attached to proteins 
and lipids. The exposed termini of oligosaccharides are often capped sialic acid-
residues believed to have evolved relatively late in evolution. Fossil records report of 
sialic acid in deuterostome lineage animals such as starfish (Schauer and Kamerling 
1997). 
The term sialic acid is a general term for sugars encompassing nine carbons. 
Mammals possess different types of sialic acids and sialic acid can occur in different 
linkages. Usually, they are exposed at the non-reducing ends of oligosaccharide 
chains attached to the surface of a wide variety of proteins and cell types. One of 
their functions is to act as ligands on the cell surface to mediate selective cell-cell 
communication and interaction. In addition, they prevent cell-cell-interactions by 
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masking subterminal sugars (Kelm and Schauer 1997; Schauer and Kamerling 
1997).  
 
                                     
 
Figrue 1.4: Schema of sialic acid with a nine carbon backbone. In mammals sialic acid is 
commonly modified at the R and R’ positions with the residues indicated in the grey box (modified 
from Crocker et al., 2007).  
 
In some pathogens the expression of sialic acid is essential for pathogenicity and 
survival within the microenvironment of the host. Via sialic acid pathogens mimic the 
surface of host cells and thereby circumvent the detection by the host immune 
system; they prevent complement activation and attenuate antibody (ab) production. 
Some pathogenic bacteria synthesize their own sialic acids, others transfer sialic 
acids from the host cell surface using a trans-sialidase (Crocker and Varki 2001a). 
Another hypothesis is that the sialic acid residues on pathogens interact with the 
inhibitory CD33-related Siglecs to trigger a reduced activation response and as an 
outcome an improved pathogen survival within the host (Crocker and Varki 2001b). 
 
1.3.2 Nomenclature and subfamilies of Siglecs 
I-type lectins are defined as glycan-binding proteins that belong to the 
immunoglobulin superfamily. Among the I-type lectins there is a distinct subfamily of 
surface receptors that share structural and functional similarities - the Siglecs. 
Siglecs were separately discovered by two studies on a macrophage lectin-like 
adhesion molecule named sialoadhesin and a B-cell restricted member of the 
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immunoglobulin superfamily CD22 (Crocker and Gordon 1986; Stamenkovic and 
Seed 1990). Siglecs are characterized by a V-set Ig-like domain mediating sialic acid 
recognition and binding. Following this domain they have one or more C2-set Ig-like 
domains. Criteria for the inclusion of receptors in this specific group are (i) the ability 
to bind sialylated glycans and (ii) a significant sequence similarity within the N-
terminal V-set and joining C2-set domains (Crocker et al. 1998).  
 
 
Figure 1.5: Overview of the Siglec family. The human Siglecs 2, 3 and 5-12 and the murine Siglecs 
2 and Siglec-E, -F and –G have ITIM sequences in their cytoplasmic tail whereas the human Siglecs 
14-15 and murine Siglecs 15 and –H have ITAMs and associate with the adaptor protein DNAX 
activation protein of 12 kDa (DAP12) (modified from Varki et al, 2009). 
 
During the last few years several human and mouse members of the Siglec family 
have been identified through genomic studies and functional analyses. Siglecs can 
be subdivided into two distinct groups: the common Siglecs and the CD33-related 
Siglecs. The former group consists of the human founding members of the Siglec 
family: sialoadhesin (Siglec-1), a macrophage adhesion molecule; CD22 (Siglec-2), a 
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B-cell inhibitory receptor; CD33 (Siglec-3), a marker of myeloid cells and myelin-
associated glycoprotein (MAG or Siglec-4). The latter are highly related to CD33 and 
to each other among this group and share about 50-80 % sequence similarity. They 
are a separate group not only from a functional point of view but concerning 
evolutionary perspectives as well. The nomenclature for CD33-related Siglecs is 
numerical in humans and alphabetical in mice (Crocker 2002) (Figure 1.5). 
 
1.3.3 Composition and expression of Siglecs 
Siglecs are type I transmembrane proteins, which are characterized by an N-terminal 
V-set Ig-like domain, which mediates sialic acid binding. The preference for a certain 
type of sialic acid is determined by a sequence of six amino acids in the C-C´ loop of 
the V-set domain (Yamaji et al. 2002). The V-set is followed by a varying number of 
C2-set Ig-like domains from which is believed that they have evolved through 
repeated gene duplications. In the mouse the number varies between 4 C2-set Ig-like 
domains in Siglec-G and only one in Siglec-H. For the human sialoadhesin even 16 
C2-set Ig-like domains have been reported (Crocker et al. 2007) (Figure 1.5). 
Collectively, the CD33-related Siglecs are expressed broadly in the innate immune 
system, but are strikingly absent from most T lymphocytes (Crocker and Varki 
2001b). Some Siglecs are expressed on a broad range of cells; others are expressed 
in a much more specific pattern, e.g. human Siglec-9 is found on neutrophils, 
monocytes and a fraction of natural killer (NK) and B cells and a subset of T cells 
(Zhang et al. 2000). Quite the contrary is true for Siglec-8, which is expressed on 
circulating eosinophils and hence in a much more restricted pattern (Floyd et al. 
2000). Some cell types express more than one type of Siglec receptors. But of the 
CD33-related Siglecs, every receptor exhibits a specific expression pattern among 
hematopoietic cells. 
Concerning their cytosolic tail, Siglecs vary in sequence and length, although most of 
the CD33-related Siglecs share regions of sequence similarity surrounding their two 
conserved ITIMs. The genes encoding human Siglecs are on chromosome 20p 
(sialoadhesin) or 19q (all other Siglecs) and those encoding the murine Siglecs are 
on chromosomes 2 and 7 (Crocker 2002). 
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1.3.4 Function in the immune system 
Siglecs recognize different forms and linkages of sialic acids that are commonly 
found on the cell surface. Siglec binding sites can be masked by cis interactions with 
sialic acids on the same cell, which then prevent them from mediating cell-cell 
interactions. Studies indicate that most Siglecs on resting cells indeed exist in a 
masked form. Unmasking them may occur during cellular activation (Crocker et al. 
1995; Crocker and Gordon 1986). Therefore, cis interactions could potentially 
regulate Siglec functions (Figure 1.6). 
 
                               
 
 
Figure 1.6: Cis and trans interactions of Siglecs.  Most Siglecs found on cells are in a masked form 
due to cis-interactions with sialic acids expressed on the cell surface of the same cell. Treatment with 
sialidase or cellular activation leads to unmasking of the Siglecs and enables them to bind to their 
ligand in trans (modified from Crocker et al., 2007). 
 
In case the receptor becomes unmasked it can bind to its target in trans on another 
cell surface; the signalling cascade via the cytosolic ITIM gets activated and the 
inhibitory effect that antagonizes the ITAM receptor is executed. It is believed that 
Masked 
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Siglecs could play a role in the regulation of the innate immune system. For example, 
CD22 is a B-cell inhibitory receptor and contains three ITIMs. The ITIMs associate 
with the B-cell receptor (BCR) and inhibit cellular activation (Crocker 2002). In 
contrast, another study could show that a sialic-acid-based CD22-specific inhibitor 
caused heightened activation of B cells in response to BCR cross-linking, which is 
accompanied by hypophosphorylation of CD22 and reduced recruitment of SHP-1 
(Kelm et al. 2002).  
Artificially cross-linking of FcRI with antibodies results in reduced Ca2+ influx 
(Ulyanova et al. 2001). Similarly, when clustering Siglec-7 with a cross-linking 
antibody, cytotoxicity of NK cells can be inhibited (Falco et al. 1999). Addition of an 
antibody against human CD33 or against Siglec-7 to haematopoietic cell cultures 
leads to reduced cell growth and inhibition of dendritic cell development (Ferlazzo et 
al. 2000; Vitale et al. 1999).  
Additionally sialic acids might act as broadly expressed “self” ligands that interact 
with CD33-related Siglecs on myeloid cells. Thereby, they could prevent 
inappropriate self-reactivity.  
 
1.3.5 Siglec-E 
Siglec-E was first identified by Ulyanova and colleagues in 2001. In the beginning 
Siglec-E was called MIS (a myeloid inhibitory siglec) (Ulyanova et al. 2001). Siglec-E 
consists of seven exons spanning approximately 9.1 kilobases (kb). The messenger 
ribonucleic acid (mRNA) transcript has a length of 2.0 kb and the encoded protein is 
467 amino acids long and has a molecular weight of ~80-85 kilo Dalton (kDa). In vivo 
it exists as a disulfide-linked oligomeric complex with at least two molecules of 
Siglec-E (Yu et al. 2001). From the sequence, an extracellular domain composed of 
331 amino acids, a hydrophobic transmembrane domain containing 27 amino acids, 
and a cytoplasmic tail of 93 amino acids was predicted. The sequence starts with a 
hydrophobic signal peptide and harbours ten potential N-glycosylation sides 
(asparagine (N)-X-serine (S)/threonine (T)) in the extracellular region of the protein. 
By its migration properties in a SDS-PAGE it was confirmed that Siglec-E is indeed 
glycosylated. It most closely resembles the human Siglecs 7 and 9 with an overall 
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sequence identity of 52 % and 53 % and exhibits combined features of both (Zhang 
et al. 2004) (Figure 1.5 and 1.7). 
Siglec-E binds alpha2-8 linked sialic acid preferentially to alpha2-3 and alpha2-6- 
linked sialic acid (Zhang et al. 2004). The amino acids, which are indispensable for 
binding of sialic acid, are conserved in Siglec-E at position 126 (arginine), at position 
25 (phenylalanine) and at position 134 (tyrosine). Additionally, cysteine residues, 
which are conserved in the Siglec family, are found in Siglec-E (Yu et al. 2001). 
 
 
                                                            
 
Figure 1.7: Murine Siglec-E. The murine receptor Siglec-E is a type I transmembrane protein with 
three extracellular domains. The N-terminal domain mediates sialic acid binding and is followed by two 
Ig-like domains. In its intracellular part it harbours one ITIM sequence and one ITIM-like sequence 
(modified from Crocker et al., 2007). 
 
Siglec-E is highly expressed in the spleen and on mature cells of the innate immune 
system, including the cell types that express either hSiglec-7 and/or -9 such as 
phagocytic cells and on antigen-presenting cells including macrophages and 
dendritic cells (DCs) (Zhang et al. 2004). 
The ITIMs of Siglec-E recruit SHP-1 and SHP-2. SHP-1 is recruited either through its 
membrane-proximal ITIM (centred at Y-432) or the membrane-distal ITIM (centred at 
Y-455) (Ulyanova et al. 2001). The membrane-proximal ITIM alone is sufficient for 
binding of SHP-1 (Zhang et al. 2004). Each SH2 domain of SHP-1 is capable of 
binding to the membrane-proximal ITIM, whereas only the first (N-terminal) SH2 
domain is able to bind to the membrane-distal ITIM. The degree of association with 
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Siglec-E correlates with the extent of Siglec-E tyrosine phosphorylation (Ulyanova et 
al. 2001). 
A study of Boyd and colleagues demonstrated that the expression of Siglec-E is 
induced after stimulation with TLRs in a MyD88-specific manner. Once up-regulated, 
it can control/inhibit TLR-induced NF-κB and the induction of the antiviral cytokines 
Interferon-β (IFN-β) and RANTES (regulated on activation, normal T cell expressed 
and secreted). Hence Siglec-E seems to be capable of controlling the antiviral 
response to TLRs and thereby helps to maintain a healthy cytokine balance following 
infection (Boyd et al. 2009). 
In a recent publication another functional aspect of Siglec-E was shown. Siglec-E 
deficient mice showed a higher neutrophil recruitment to the lung in an acute lung 
inflammation model induced by aerosolised LPS (McMillan et al. 2013). This effect 
was mediated by negative regulation of the adhesive function of the integrin CD11b 
by Siglec-E, indicating an important role of Siglec-E in the regulation of the 
inflammatory response to lung inflammation to prevent an over-activation of the 
immune system. 
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1.4 Aim of the study 
Microglia are cells of the innate immune system and build the first line of defence in 
the CNS. Their duty is on the one hand homeostasis and defence against pathogens 
on the other. To be able to fulfil their duties, they have immune receptors on their 
surface, recognizing pathogen and disease-associated molecular patterns, but have 
molecules to sense intact tissue, too. Siglecs are one of these receptor families on 
microglia. One member of this family is the murine Siglec-E.  
So far there are no data about Siglec-E on microglial cells. Therefore, the aim of this 
study was to investigate the role of Siglec-E on microglia in neuroinflammation. The 
questions to be answered were, which regulatory role Siglec-E might play on 
microglia in the CNS and what are the consequences for neurons in the brain in a co-
culture setting. 
For this purpose, we first had to prove that there is indeed Siglec-E expression on 
microglia. To get an idea about the functional role, we performed lentiviral knock-
down and overexpression studies. The modified microglia were analysed for changes 
in cytokine transcription and surface marker expression. We looked for differences in 
phagocytic behaviour and the associated burst of reactive oxygen species in these 
modified microglia. 
After we discovered that a recombinant Siglec-E:Fc fusion protein is able to bind to 
sialic acids on neuronal surfaces, we started co-culture experiments with primary 
neurons in which we mimicked the state of neuronal damage. Scavenging 
experiments were done with an anti-oxidant. By measuring the neurite length we 
evaluated the effect of Siglec-E knock-down and overexpression.  
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2. Materials and Methods   
  
2.1 Materials  
2.1.1 Chemicals and Reagents  
 
Chemical Company 
Agarose   Biozym, Germany 
Ampicillin Sigma, Germany 
Amplex Red Invitrogen, Germany 
Avertin (2, 2, 2-tribromoethanol) Sigma, Germany 
B-27® Supplement Gibco, Germany  
Basal Medium Eagle (BME) (1x), liquid Gibco, Germany 
Boric Acid (H3BO3) Sigma, Germany 
Bromophenol Blue Sigma, Germany 
CellTracker™ CM-Dil, 1 mg Life Technologies, Germany 
Chloroquine diphosphate salt   Sigma-Aldrich, Germany  
DABCO   Sigma, Germany 
4',6-diamidino-2-phenylindole (DAPI) Sigma Aldrich Chemie GmbH, 
Germany 
ddH2O Roth, Germany 
dihydroethidium (DHE)   Invitrogen GmbH, Germany 
D-Glucose (45 %) Sigma, Germany 
DMEM/F12 (1:1) Gibco, Germany 
DMSO for molecular biology, >= 99.9 % Sigma, Germany 
dNTP Mix (10 mM)   Sigma, Germany 
DTT (10 mM) Invitrogen, Germany 
Dulbecco’s Modified Eagle Medium (D-MEM) 
(1x), liquid (4.5 g/L D-glucose)  
Gibco, Germany  
 
Ethanol (C2H6O) Roth, Germany 
Ethidium Bromide (10g/l) Roth, Germany 
Ethylendiamintetraacetate (EDTA) Roth, Germany 
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Fetal Bovine Serum (FBS) Gibco, Germany  
Fetal Bovine Serum, ultra-low IgG Gibco, Germany  
Ficoll-400 Bio-Rad, Germany 
First Strand Buffer (5x) Invitrogen, Germany  
Glycerol Sigma, Germany 
Hank’s Balanced Salt Solution (HBSS) (1x) Gibco, Germany  
HBSS (10x) Gibco, Germany  
Hexanucleotide Mix (10x) Roche, Germany 
L-Glutamine (200 mM) Sigma, Germany 
LB Agar Sigma, Germany 
LB Broth Sigma, Germany 
Lipofectamine™ Transfection Reagent Gibco, Germany  
MEM nonessential amino acid solution (100x) Gibco, Germany  
MEM sodium pyruvate solution (100 mM) Gibco, Germany  
Mowiol Kremer Pigmente, Germany 
okadaic acid Sigma, Germany 
Opti-MEM® I Reduced-SerumMedium (1x), liquid  Gibco, Germany  
Paraformaldehyde (PFA) Sigma, Germany  
Penicillin/Streptomycin (100x) Gibco, Germany  
Percoll™ GE Healthcare, Germany 
Polybrene Sigma, Germany 
poly-L-Lysine   Sigma, Germany  
Sodium chloride (NaCl) Roth, Germany  
Sodiumhydrogenphosphate (NaH2PO4*H2O)  Roth, Germany  
Sodiumhydrogenphosphate (NaH2PO4*7H2O)     Roth, Germany  
Sodium hydroxid (NaOH) Roth, Germany  
Sucrose Roth, Germany 
SYBR Green Master Mix (2x) Applied Biosystems, Germany  
tert-amyl alcohol (2-methyl-2-butanol) Fisher, Germany 
Tris base Roth, Germany  
Tris buffer, 0.2 M Roth, Germany  
Trypan Blue Gibco, Germany  
Xylene Cyanole Sigma, Germany  
Zeocin InvivoGen, USA 
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2.1.2 Buffers and solutions  
  
10x (0.125 M) Phosphate  0.007 M NaH2PO4*H2O  
buffered saline (PBS), pH 7.3  0.034 M NaH2PO4*7H2O  
     0.6 M NaCl 
 up to 1 litre ddH2O 
   
2x HBS  8 g NaCl 
 0.38 g KCl 
 0.1 g Na2HPO4 
 5 g Hepes 
 1 g glucose 
 up to 500 ml ddH2O  
 adjust pH to 7.05 
   
4% Paraformaldehyde (PFA),  20 g    PFA 
pH 7.3   30 ml    NaOH 
 50 ml    PBS (10x) 
 up to 1 litre ddH2O   
   
Mowiol    4.8 g    mowiol 
    12 g    glycerol 
    12 ml    ddH2O 
    24 ml    0.2 M tris buffer 
 1.32 g    DABCO 
   
   
10x Tris/Borate/EDTA (TBE)  1.78 M    tris-Base 
buffer   1.78 M    boric Acid 
 0.04 M    EDTA 
 up to 2 litres ddH2O 
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6x Loading buffer         0.5 M EDTA 
    60 % (w/v) sucrose 
 0.04 % (w/v) bromophenol blue 
 0.04 % (w/v)  xylene cyanole 
      2 % (v/v)  Ficol-400 
   
1% Agarose gel 0.5 g agarose 
    4 µl ethidium bromide 
  50 ml TBE (1x) 
   
Real time polymerase chain       3 µl cDNA (200 ng/µl)  
reaction (RT-PCR) mix 12.5 µl SYBR Green Master Mix (2x)  
      2 µl  primer Mix (10 pmol/µl)  
   7.5 µl ddH2O  
   
Reverse transcription (RT) mix 5 µg total RNA 
 1 µl hexanucleotide Mix (10x) 
 1 µl dNTP Mix (10 mM) 
 2 µl DTT (10 mM)  
 4 µl 5x RT first strand buffer  
 1 µl reverse transcriptase (200 U/ml)  
 up to 20 µl ddH2O  
   
Avertin stock solution     25 g avertin (2, 2, 2-tribromoethanol) 
 15,5 ml tert-amyl alcohol (2-methyl-2-
butanol) 
 
 2.1.3 Cell culture media and reagents  
 
N2 medium     500 ml DMEM/F12 (1:1) 
 0.048 mM L-Glutamine (200 mM) 
 15.3 µg/ml  D-Glucose (45%) 
 1 % (v/v) Penicillin/Streptomycin (100x) 
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MEF medium       450 ml DMEM high glucose 
 10 % (v/v) Fetal Bovine Serum 
   1 % (v/v) L-Glutamine (200 mM)  
   1 % (v/v) MEM nonessential amino acid solution (100x)  
   1 % (v/v) MEM sodium pyruvate solution (100 mM)  
   
Trans-MEF medium       500 ml DMEM high glucose 
   5 % (v/v) Fetal Bovine Serum 
   1 % (v/v) L-Glutamine (200 mM)  
   1 % (v/v) MEM nonessential amino acid solution (100x)  
   1 % (v/v) MEM sodium pyruvate solution (100 mM)  
      50 nM chloroquine 
   
Primary microglia       450 ml BME 
medium  10 % (v/v) Fetal Bovine Serum 
   1 % (v/v) L-Glutamine (200 mM)  
   2 % (v/v) D-Glucose (45%) 
   1 % (v/v) Penicillin/Streptomycin (100x)  
   
Neuron medium     500 ml BME 
   1 % (v/v) Fetal Bovine Serum 
   1 % (v/v) D-Glucose (45%) 
   2 % (v/v)  B-27 
 
2.1.4 Cell lines and bacterial strains  
 
Cell line/Bacterial Strain  Source 
Chinese Hamster Ovary (CHO) cells Jerome Mertens (AG Brüstle)  
Embryonic Stem Cell-derived Microglia (ESdM)      Clara Beutner (AG Neumann)  
GL261 Hertie-Institute for clinical 
neurology, Germany 
HEK293FT Invitrogen, Germany 
OneShot® Top10 Chemically Competent E. coli     Invitrogen, Germany  
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SMA560 Hertie-Institute for clinical 
neurology, Germany 
 
2.1.5 Antibodies, enzymes, recombinant proteins and stimulants  
2.1.5.1. Primary Antibodies  
Antibody Host Reactivity Company 
anti-mouse-Fc rabbit mouse Dianova, Germany 
βIII-tubulin mouse mouse Sigma, Germany 
CD11b-biotinylated rat mouse BD Biosciences, Germany 
CD11b-phycoerythrin (PE) rat mouse eBioscience, USA 
CD11c-biotinylated hamster mouse BD Biosciences, Germany 
CD16/32 rat mouse BD Biosciences, Germany 
CD18-biotinylated rat mouse BD Biosciences, Germany 
CD31-biotinylated rat mouse BD Biosciences, Germany 
CD34-biotinylated rat mouse BD Pharmingen, Germany 
CD45-biotinylated rat mouse BD Biosciences, Germany 
CD45-V450 rat mouse BD Biosciences, Germany 
CD68 rat mouse AbD serotec, USA 
CD80-biotinylated hamster mouse BD Biosciences, Germany 
CD86-biotinylated rat mouse BD Biosciences, Germany 
F4/80-biotinylated rat mouse Serotec, Germany 
GFAP mouse mouse abcam 
Iba1 rabbit mouse Wako, Germany 
Siglec-E   rat mouse MBL International, Japan  
       
2.1.5.2 Isotype controls 
Antibody Host Reactivity Company 
isotype IgG2bκ    rat  BD Biosciences, Germany 
isotype IgG2bκ-PE rat  BD Biosciences, Germany 
isotype IgG2bκ-V450 rat  BD Biosciences, Germany 
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2.1.5.3 Secondary Antibodies      
Fluorophore Host   Reactivity Company 
Alexa488 Goat Rabbit Invitrogen, Germany  
anti-rat-biotinylated goat rat Dianova, Germany 
Cy3 Goat Rat Dianova, Germany 
Cy3 Goat Mouse Dianova, Germany 
FITC Goat Rat Dianova, Germany 
PE Goat Rat JacksonImmuno, USA 
PE-Streptavidin   JacksonImmuno, USA 
Alexa647-Streptavidin   JacksonImmuno, USA 
           
2.1.5.4 Enzymes, recombinant proteins    
Enzyme   Company  
BamHI (10 U/µl) Roche, Germany  
BglII (10 U/µl) New England Biolabs, Germany 
Catalase Serva, Germany 
DNase I, RNase-free, lyophilized Qiagen, Germany 
EcoRI (10 U/µl) Roche, Germany 
EcoRV (10 U/µl) Roche, Germany 
EndoN (EC 3.2.1.129) Abcys, France 
HindIII (10 U/µl) Roche, Germany 
Neuraminidase (Sialidase; EC 3.2.1.18) from 
Arthrobacter ureafaciens  
Roche, Germany 
Neuraminidase (EC 3.2.1.18) from Clostridium 
perfringens 
New England Biolabs, Germany 
Peroxidase from Horseradish Sigma, Germany 
PinAI (AgeI) (10 U/µl) Roche, Germany 
Platinum Taq DNA Polymerase High Fidelity Invitrogen, Germany  
Recombinant mouse Siglec-E Fc chimera, CF R & D Systems, Germany  
Recombinant mouse Siglec-F Fc chimera, CF R & D Systems, Germany  
Reverse Transcriptase (200 U/ml) Invitrogen, Germany 
SfuI (AsuII) (10 U/µl) Roche, Germany  
Superoxide dismutase from bovine Serva, Germany 
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erythrocytes 
T4 DNA Ligase Invitrogen, Germany  
XhoI (10 U/µl) Roche, Germany  
    
2.1.5.5 Stimulants  
Stimulant Company  
LPS S. enterica serotype abortus equi  
(1000 µg/ml) 
Sigma, Germany  
Recombinant  murine  IFN-α,  CHO  derived  
(106 U/ml)  
Hycult  Biotechnology, Netherland  
 
Recombinant  murine  IFN-γ,  CHO  derived  
(106 U/ml)   
Hycult  Biotechnology, Netherland  
Recombinant murine TNF-α (10 µg/ml) R & D Systems, Germany  
 
2.1.6 Primer  
2.1.6.1 Quantitative Real-Time PCR Primer  
Target Orientation Sequence 
GAPDH forward 5’ – ACAACTTTGGCATTGTGGAA – 3’ 
 reverse 5’ – GTCTTGTAGTAGGGACGTAG – 3’  
IL-1β forward 5’ – ACAACAAAAAAGCCTCGTGCTG – 3’ 
 reverse 5’ – TGAAAGCTCTCCACCTCAATGG – 3’ 
iNOS forward 5’ – AAGCCCCGCTACTACTCCAT – 3’ 
 reverse 5’ – TTGGATCAGGAACCTGAAGC – 3’ 
Siglec-E forward 5’ – TCTGAGGGCCAGTCACTGCGT – 3’ 
 reverse 5’ – GGACAGAGGTGTCTCGTCACGTT – 3’ 
TNF- α forward 5’ – TCTTCTCATTCCTGCTTGTGG – 3’ 
 reverse 5’ – AGTTCTATGGCCCAGACCCT – 3’ 
    
 
   
2. Materials and Methods 23 
 
2.1.6.2 Cloning Primer      
Target Orientation Sequence 
Igκ EcoRI fwd forward 5’ – CATGAATTCACCATGGAGACAGACACA 
CTCCTG – 3’  
SigE flag fw XhoI forward 5’ – CATCTCGAGACCATGCTGCTGTTGCTG 
CTGC – 3’  
SigE flag rv SfuI reverse 5’ – CATTTCGAATCCTCCTCCTCCTCCTCC 
TGGCCATGCGGTCCTTTG – 3’  
SigE pll fw AgeI  forward 5’ – CATACCGGTACCATGCTGCTGTTGCTG 
CTGC – 3’  
SigE pll rv AgeI reverse 5’ – GTTTCCTGGCGTACCGGTCCTCCTCCT 
CCTGGCCATAC – 3’   
       
 2.1.6.3 Sequencing Primer      
Target Orientation Sequence 
hIgG1-Fc rv seq        reverse 5’ –  CGTAGTGTTTAAAGTGTTTATTTCG – 3’  
SigE F1 seq   forward 5’ –  CATCATATGCTGCTGTTGCTGCTGC – 3’  
SigE F2 seq   forward 5’ – GCTCCAAAGAATCTGACTGTGAC – 3’   
SigE R1 seq   reverse 5’ – CGTTGGACTGGACGAGAC – 3’ 
      
 2.1.7 Consumables  
Product Company 
0.22 µm pore size filter stericup Millipore, USA  
100 Sterican 20Gx2 ¾ 0,9x70 mm Braun Melsungen AG 
2 ml, 5 ml, 10 ml, 25 ml plastic pipets Costar, Germany  
5 ml polystyrene round-bottom tubes BD Falcon, Germany  
6-well culture plates Cellstar, Germany  
10 μl, 100 μl, 1000 μl pipette tips Eppendorf, Germany  
10 ml, 50 ml syringe Braun, Germany  
15 ml plastic tubes Greiner, Germany  
24-well culture plates Greiner, Germany  
50 ml plastic tubes Sarstedt, Germany  
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BD 5 ml Syringe Luer-lock Tip BD Syringe, Germany 
BD Discardit™ II Spritze Becton Dickinson GmbH 
BD Microlance™ 3 Becton Dickinson GmbH 
Bottle top filters, 0.25 µm pore Millipore, Germany  
Cell scraper Sarstedt, Germany  
Cell strainer 40 µm Nylon  BD Falcon, Germany  
Cell strainer 70 µm Nylon BD Falcon, Germany 
Chamber slides Nunc, Germany 
Cryovials VWR International, Germany 
Dermaclean Untersuchungshandschuhe   Ansell, Germany 
Erlenmeyer flask, 250 ml Schott-Duran, Germany 
Glass cover slides 24x24 mm VWR International, Germany 
Glas pasteur pipettes Brand, Germany 
Injection needles Braun, Germany  
MicroAmp® 96-well Optical Adhesive Film Applied Biosystems, USA  
MicroAmp® optical 96-well plate Applied Biosystems, USA  
NitraTex® Nitril-Untersuchungshandschuhe Ansell, Germany  
Optical Adhesive Covers Applied Biosystems, USA  
PCR tubes, 500 µl  Biozym Diagnostics, Germany  
Petri dishes 100x15 mm BD Falcon, Germany  
Tissue culture dish 60x15 mm Sarstedt, Germany 
Tissue culture dish 100x20 mm Sarstedt, Germany 
Tissue culture dish 150x20 mm   TPP, Germany  
Tubes 1.5 ml, 2.0 ml   Eppendorf, Germany  
  
2.1.8 Equipment     
Equipment Company 
Agagel Standard   Biometra, Germany  
BD Facs Calibur   BD Bioscience  
BD Facs CantoII BD Bioscience 
Biofuge Fresco   Heraeus, Germany  
BL 610   Sartorius, Germany  
Electrophoresis Power Supply EPS-301   Amersham Bioscience, Germany 
Fluoview1000 Confocal microscope Olympus, Germany 
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Freezer -80°C Herafreeze Heraeus, Germany 
Heating block Stuart Scientific, Germany  
HeraCell 240 Heraeus, Germany  
HI 9321 Microprocessor pH meter Hanna Instruments, Germany  
Kompaktschüttler KS-15 Control Edmund Bühler, Germany  
Mastercycler epgradient S Eppendorf, Germany  
Megafuge, 1.OR.   Heraeus, Germany  
Neubauer chamber Brand, Germany  
Operating microscope OPMI-FR Zeiss, Germany  
Pumpdrive 5001 Heidolph, Germany 
Roto-Shake Genie Scientific Industries Inc., USA  
Shimadzu RF 5001PC spectrofluorimeter Shimadzu, USA 
Sorvall Discovery 90SE Hitachi, Germany  
Standard Power Pack P25 Biometra, Germany  
Thermocycler T3 Biometra, Germany 
Thermomixer compact Eppendorf, Germany  
Vortex Genie2 Scientific Industries Inc., USA  
Waterbath Modell WB 7   Memmert, Germany 
XCell II™ Mini-Cell Blot Module Kit CE Mark   Invitrogen, Germany    
XCell II™ Mini-Cell SureLock® Retrofit Kit   Invitrogen, Germany  
   
2.1.9 Kits, Marker and Vectors     
Name Company 
DNA Molecular Weight Marker XIV (100 bp ladder) Roche, Germany 
pll3.7 U6 removed   Yiner Wang, AG Neumann  
PureLink™ HiPure Plasmid Filter Maxiprep Kit  Invitrogen, Germany  
QIAprep Spin Miniprep Kit  Qiagen, Germany  
QIAquick Gel extraction Kit  Qiagen, Germany   
RNeasy Mini Kit Qiagen, Germany   
RNeasy Lipid Tissue Mini Kit Qiagen, Germany  
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2.1.10 Software    
Software Company 
Adobe Illustrator™CS3 Adobe 
Adobe Photoshop™CS3 Adobe  
ApE M. Wayne Davis 
EndNote X1 Thomson ISI ResearchSoft,  
USA 
FlowJo 6.4.7 Tree Star, USA  
ImageJ 1.43m National Institute of Health, 
USA 
Microsoft Office Microsoft, USA 
Olympus FluoView 1.4 Olympus, Germany  
QuantityOne Bio-Rad, Germany 
SPSS IBM, Germany 
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2.2 Methods  
  
2.2.1 Isolation of primary microglia and neurons 
Primary neuronal cultures were obtained from embryonic mice at day 14 or 15 of 
C57BL/6 mice while primary microglia were prepared from brains of postnatal day 3 
or 4 (P3 or P4) of C57BL/6 mice. In brief, the brains were isolated and only the two 
hemispheres were used. The meninges were removed mechanically and cells were 
dissociated by trituration and cultured in basal medium for 14 days to form a 
confluent mixed glial monolayer. For neuronal cultures only the hippocampus and 
cortex were used, for primary microglia both hemispheres without cerebellum and 
olfactory lobes were prepared. 
To collect microglial cells, the cultures were shaken on a rotary shaker (350 rpm) for 
3 hours. The detached microglial cells were either used directly for flow cytometry 
analysis or seeded on poly-L-lysine (pLL) coated culture dishes at 37°C in 5 % CO2 
for stimulation and RNA isolation.  
 
2.2.2 Ex vivo isolation of brain cells 
Three weeks old C57/BL6 mice were perfused with HBSS and the brain was 
prepared without cerebellum. The brain was homogenized in HBSS and centrifuged 
for 7 minutes at 300g. The pellet was resuspended in 37 % percol and loaded onto a 
percol gradient consisting of HBSS, 30 % percol, 37 % percol and 70 % percol (from 
top to bottom). Via centrifugation in this percol gradient for 40 minutes at 200g 
without brake, mononuclear cells of the brain were enriched in a ring between the 
37 % and 70 % phase. The mononuclear cells were aspirated and washed three 
times with HBSS. After the final washing step the cell pellet was resuspended and 
further stained for flow cytometry with antibodies directed against CD11b, CD45 and 
Siglec-E. Microglia were gated as CD11b+ and CD45low cells. 
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2.2.3 Culturing of microglial cells 
The microglia line was cultivated in N2 medium in an incubator with 5 % CO2 at 
37°C. Upon 80-90 % confluence the cells were splitted 1:10 using a cell scraper until 
they were confluent again. For freezing of cells the N2 medium was supplemented 
with 10 % DMSO and 40 % FBS. Cells were stored for at least three days at -80°C 
and then transferred to liquid nitrogen for long term storage. 
 
2.2.4 Immunocytochemistry of cultured cells   
Cells were fixed on a chamber slide in 4% PFA for 10 minutes, blocked by 10x 
bovine serum albumin (BSA) and immunostained with a primary antibody in 1x BSA 
overnight at 4°C followed by the secondary antibody at room temperature for 2 hours. 
Nuclei of immunostained cells were subsequently labelled with 4', 6-diamidino-2-
phenylindole (DAPI) for 30 seconds and slides covered with cover slips and mowiol.  
Images were collected by confocal laser scanning microscopy (Fluoview 1000, 
Olympus) or fluorescence microscopy.  
  
2.2.5 Flow cytometry analysis    
Microglia were collected from culture dishes by a cell scraper. For flow cytometry 
analysis of ex vivo microglia cells were isolated as described above. After Fc-
receptor blocking for 5 minutes with a CD16/32 antibody cells were incubated with an 
anti-Siglec-E and a biotin-conjugated antibody directed against the Siglec-E antibody. 
This was followed by a triple staining with a PE-conjugated anti-CD11b, a V450-
conjugated anti-CD45 and Alexa647-conjugated streptavidin. Isotype matched 
control antibodies were used as negative controls. Analysis was done with a FACS 
Calibur or FACSCantoII flow cytometer (both BD Bioscience) and FlowJo Software 
(BD Bioscience).  
  
2.2.6 Analysis of gene transcripts by quantitative real-time polymerase chain 
reaction (qRT-PCR)     
Microglia were seeded at a density of 250 000 cells/well in a 6-well plate and for the 
analysis of Siglec-E transcription they were stimulated with either 500 ng/ml LPS, 
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100 U/ml IFN-, 1000 U/ml IFN- or 20 ng/ml TNF-. Unstimulated cells served as a 
control. After 24 hours of stimulation RNA was isolated using the RNeasy Mini Kit. 
Reverse transcription of RNA was performed with SuperScript III reverse 
transcriptase and hexamer random primers according to the Invitrogen protocol for 
SuperScript First-Strand Synthesis. The concentration of transcribed cDNA was 
adjusted to 200 ng/µl.  
Gene transcripts of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were applied as internal RNA control. qRT-PCR with 
specific oligonucleotides was performed with SYBR Green PCR  Master Mix using 
the ABI 5700 Sequence Detection System and amplification protocol for the ABI 
5700 Sequence Detection System. For quantitative real-time PCR the following mix 
was prepared in a 96-well-plate: 
12.5 µl SYBR Green Mix 
1 µl forward primer (10pmol/µl) 
1 µl reverse primer (10pmol/µl) 
3 µl  cDNA (200 ng/µl) 
7.5 µl aqua destillata (dest.) 
 
For the non-template control the cDNA was replaced with aqua dest. The plate was 
covered with a plastic lid and analysed with the following program: 
 
Cover T° = 105°C  
 
  
Initial denature 95°C 08:30 min 
Denature 95°C 00:15 min 
Annealing 60°C 00:30 min 
Elongation 72°C 00:30 min 
Amplification for 40 cycles  
  
 
To ensure that a specific product was obtained a dissociation curve analysis was 
performed using the following program:  
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 95°C 01:00 min 
 55°C 00:15 min 
 95°C 00:15 min 
ramp rate  20:00 min 
 
Amplification specificity was confirmed by analysis of the melting curves. Results 
were analysed with the ABI 5700 Sequence Detection System v.1. after establishing 
the reaction efficiency for each primer pair. Quantification using the -CT method 
was carried out.   
 
2.2.7 Plasmid construction  
The pll3.7 vector was modified to contain a neomycin resistance gene by replacing 
the U6 promoter with a cassette of phosphoglycerate-kinase (PGK) promoter. 
Plasmids expressing green fluorescent protein (GFP) or Siglec-E (AG Fleischer, 
Hamburg) linked to GFP were cloned based on the modified pll3.7 backbone with a 
cytomegalovirus (CMV) promoter (Figure 2.1).  
 
 
Figure 2.1: Schematic drawing of the vector backbone used for overexpression of Siglec-E.  
The vector pll3.7 has a CMV promotor, a GFP and a neomycin resistance under the PGK promotor.  
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Described genes or fragments were obtained from corresponding constructs by PCR 
using primers including restriction sites allowing the product to be inserted into the 
vector by specific digest.  
The standard PCR mix was as follows: 
36.3 µl aqua dest. 
5 µl 10x High Fidelity PCR buffer 
2 µl dNTP mix (10 mM) 
2 µl MgSO4 (50 mM) 
2 µl forward primer (10pmol/µl) 
2 µl reverse primer (10pmol/µl) 
0.5 µl  cDNA (1 µg/µl) 
0.2 µl Platinum Taq High Fidelity 
  
The following PCR program was used: 
Initial denature 94°C 02:00 min 
Denature 94°C 01:30 min 
Annealing according to primer 01:00 min 
Elongation 68°C 1 min/1000 bp 
Final elongation 68°C 10:00 min 
Amplification for 40 cycles  
 
The subsequent ligation was performed in a molecular ratio from vector:insert of 1:1, 
1:2 and 1:4. The ligated vectors were transformed into Top10 competent bacteria. 
Positive colonies selected by antibiotics were inoculated in a small volume. Plasmid 
DNA was isolated and digested using the corresponding restriction enzymes. 
Colonies having the insert were expanded and purified using PureLink™ HiPure 
Plasmid Filter Maxiprep Kit. The sequence of each plasmid was verified further by 
sequencing.  
For knock-down of Siglec-E the vectors including the target sequence were obtained 
by AG Hornung, Bonn (Figure 2.2). 
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Figure 2.2: Schematic drawing of the vector backbone used for knock-down of Siglec-E. For the 
production of short hairpin constructs the vector pLKO.1 was used (source: addgene). 
 
2.2.8 Viral particle production   
For the production of lentiviral particles 6.5 x 106 HEK293FT cells were seeded on 
15 cm-dishes pre-coated with pLL. The HEK293FT packaging cell line was kept 
overnight in MEF medium at 37°C in 5 % CO2. The following day 25 μg of targeting 
plasmid together with 25 μg pLP1, 12.5 µg pLP2 and 15 µg pLP/VSVG were 
incubated with 1047.5 µl ddH2O, 125 µl 2.5 M CaCl2 and 1250 µl 2x HBS for 25 
minutes at room temperature. The transfection mix was added dropwise to the cells. 
Cells were transfected in Trans-MEF medium containing only 5% FBS and 50 nM 
chloroquine. Medium was replaced by fresh MEF medium the following day. Viral 
supernatant was collected at 48 and 72 hours post-transfection and either 
immediately applied to transduce cells or stored at -80°C.  
  
2.2.9 Lentiviral transduction of the microglia line ESdM   
Microglia were seeded at 250 000 cells/well into 6-well plates. In total, 5 ml of 
lentiviral supernatant was added to the culture and after spinfection at 1500g for 30 
minutes at 32°C incubated at 37°C and 5% CO2. Medium was changed the day after 
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lentiviral transduction and was replaced by fresh N2 culture medium. The 
transduction procedure was repeated three times.  
 
2.2.10 Phagocytosis of neural debris 
Primary neural cultures were treated with 40 nM okadaic acid for 24 hours, 
centrifuged, washed three times with PBS and the pellet was frozen at -20°C. After 
thawing, neural debris was incubated with 1 µM Dil (Derivates for Long-Term cellular 
Labelling) for 5 minutes at 37°C followed by an incubation time of 15 minutes at 4°C 
and three washing steps with PBS. Microglia were incubated with neural debris for 2 
hours at 37°C and subsequently washed three times with PBS. Cells were fixed with 
4 % PFA, washed three times with PBS and blocked with 10 % BSA for 30 minutes. 
Cells were then incubated with a primary antibody directed to iba1 in 1 % BSA over 
night at 4°C. The following day cells were washed three times with PBS and stained 
with a secondary Alexa488-conjugated antibody for 2 hours at room temperature. 
After DAPI-staining the cells were covered in mowiol. The stainings were stored at 
4°C in the dark. For analysis images (normal or z-stack, randomly selected areas) 
were obtained with a confocal laser scanning microscope. For quantification of the 
phagocytosis rate seven images per condition per experiment and 21 images per 
condition in total were taken maintaining the same settings. Quantification was 
performed using ImageJ software comparing phagocytosing to non-phagocytosing 
cells. 
 
2.2.11 Microglial-neuronal co-culture and immunocytochemistry 
Primary hippocampal neuronal cultures were either untreated or treated with 
25 mU/ml Neuraminidase for 2.5 hours at 37°C to remove sialic acids from the cell 
surface and were washed three times subsequently. For the ROS scavenging 
experiments, 40 nM Trolox was added to the medium before starting the co-culture 
experiment. Transduced microglia were added and both cell types were co-cultured 
for 48 hours at 37°C, 5 % CO2. Cells were fixed with 4 % PFA for 10-15 minutes and 
washed three times with PBS. Cells were incubated in 10 % BSA for 30 minutes for 
blocking, followed by an incubation with the primary monoclonal antibody directed to 
βIII-tubulin over night at 4°C. The next day cells were washed three times with PBS 
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and stained with the secondary Cy3-conjugated antibody followed by additional three 
washing steps and then incubated in the second primary antibody directed to iba1 
over night at 4°C. Cells were again washed three times with PBS and stained with an 
Alexa488-conjugated secondary antibody. Cells were stained with DAPI to visualise 
the nuclei and then covered in mowiol. Five images per condition per experiment (in 
total 15 images per condition) were collected by confocal laser scanning microscopy 
or fluorescent microscopy. The mean length of III-tubulin positive neurites or the 
density of III-tubulin positive cell bodies were analysed versus iba1 positive cells 
using ImageJ/NeuronJ software. 
 
2.2.12 Detection of ROS and cytokine transcript analysis during phagocytosis 
of neural debris 
Cultured microglia were incubated with 5 µg/µl neural debris for either 1 hour for 
dihydroethidium (DHE) staining or 16 hours for RNA isolation and qRT-PCR. For 
ROS scavenging experiments either 20 µg/ml superoxide dismutase (SOD1) or 
40 nM trolox were added at the same time as the neural debris. DHE is cell-
permeable and exhibits blue-fluorescence in the cytosol until oxidized. After oxidation 
it intercalates in the cell’s DNA and stains the nucleus in a bright red fluorescence. 
For detection and quantification of superoxide anion radical production 30 µM DHE 
were added and incubated at 37°C for 15 minutes. Cells were fixed with 4 % PFA 
plus 0.25 % glutaraldehyde (GAD) and analysed by confocal laser scanning 
microscopy. For the quantification of DHE staining intensity six images of each 
condition per experiment were obtained and analysed with the ImageJ software. The 
level of background staining was subtracted and the mean values of the staining 
intensities were compared. Quantification of gene transcripts was done by qRT-PCR 
(see chapter 2.2.6). 
 
2.2.13 Detection of superoxide by Amplex Red 
Analysis was done by AG Kunz, University of Bonn. Quantitative rates of superoxide 
generation of microglial cells incubated with 10 µg/ml neural debris were determined 
using a spectrofluorimeter with the Amplex Red/peroxidase-coupled method (1 µM 
Amplex Red (ex = 560 nm, em = 590 nm) + 20 units/ml horseradish peroxidase) in 
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the additional presence of 60 units/ml superoxide dismutase. Presence of an excess 
superoxide dismutase allows a quantification of superoxide production in hydrogen 
peroxide equivalents. All measurements were performed at 35 C in oxygen-
saturated PBS. The reaction was stopped by addition of 12000 U/ml catalase. The 
fluorescent signal was calibrated by known H2O2 concentrations as described 
previously (Malinska et al. 2009), allowing to express the superoxide production rate 
in hydrogen peroxide equivalents. In the calculations of quantitative superoxide 
generation rates the catalase (12,000 U/ml)-insensitive Amplex Red oxidation rates 
were always subtracted. 
 
2.2.14 Binding of Siglec-E:Fc fusion protein to primary neurons, astrocytes and 
microglia 
Neurons were either untreated or treated with 25 mU/ml Neuraminidase (A. 
ureafaciens), primary microglia and astrocytes with a combination of 1.4 µl/ml EndoN 
and 25 U/ml Neuraminidase (C. perfringens) for 2.5 hours at 37°C to remove sialic 
acids from the cell surface. After 2.5 hours cells were washed three times with PBS 
and then incubated with recombinant Siglec-E:Fc fusion protein or recombinant 
Siglec-F:Fc fusion protein as a positive control at a final concentration of 2.5 µg/ml 
(neurons) or 0.1 µg/ml (astrocytes and microglia) for 1 hour at 37°C. Cells were fixed 
with 4 % PFA, followed by three washing steps with PBS and blocking with 10 % 
BSA for 30 minutes. The primary monoclonal antibody was directed to βIII-tubulin 
(neurons), CD68 (microglia) or glial fibrillary acidic protein (GFAP; astrocytes) and 
applied in 1 % BSA over night at 4°C. The secondary Cy3-conjugated antibody was 
applied after three washing steps with PBS for 2 hours at room temperature in the 
dark. After another washing step the primary antibody directed to mouse IgG Fc was 
added over night at 4°C to the stainings with Siglec-E:Fc. An Alexa488-conjugated 
secondary antibody for Siglec-E:Fc or primary antibody directed to human IgG Fc-
FITC against Siglec-F:Fc was applied. Images were collected by confocal laser 
scanning microscopy. 
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2.2.15 Statistical analysis 
Data are presented as mean  SEM of at least three independent experiments. Data 
were analysed by ANOVA followed by Bonferroni using SPSS computer software. 
*p<0.05; **p0.01; ***p0.001. 
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3. Results 
 
The topic of the present study was to characterize the role microglial Siglec-E plays 
in neuroinflammatory processes in the brain. 
The first steps were to identify Siglec-E transcription and expression on microglia. To 
get an idea about the function of Siglec-E on microglia, lentiviral overexpression and 
knock-down constructs were designed and cloned. A microglia line was transduced 
and further characterized. We used these microglia to study the influence of Siglec-E 
expression on phagocytic behaviour and the associated burst. After it was proven 
that the Siglec-E:Fc fusion protein is able to bind sialic acids in the neuronal 
glycocalyx, co-culture experiments with primary neurons and the modified microglia 
line  were performed. Thereby the implication of the receptor Siglec-E on microglia in 
neuroinflammatory processes was analysed. 
 
3.1 Siglec-E is a regulator of the immune response 
Recent data of gene expression profiles from distinct mouse tissue macrophages 
suggest that Siglec-E can be also found in microglia (Gautier et al. 2012). Other 
studies demonstrated the regulatory function on Siglec-E in the immune system. 
Stimulation with TLRs induced Siglec-E expression and once upregulated it was 
enabled to control TLR-induced NF-κB and the induction of the antiviral cytokine 
IFN-β and RANTES. Thereby Siglec-E participated in the regulatory part of the 
antiviral response to TLRs and maintenance of cytokine levels in state of infection 
(Boyd et al. 2009). Siglec-E knock-out in mice led to an increased neutrophil 
recruitment to the lung in an acute lung inflammation model induced by LPS which 
was mediated by negative regulation of the integrin CD11b by Siglec-E (McMillan et 
al. 2013). 
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3.2 Detection of Siglec-E transcription and expression in microglia 
3.2.1 Siglec-E expression in ex vivo and primary microglia 
So far, expression of Siglec-E on microglia in the CNS has not been described. 
Therefore the first aim was to investigate the expression of Siglec-E on ex vivo and 
primary mouse microglia. To identify ex vivo microglia in a cell population enriched by 
a percol gradient cells were labelled and gated for CD45low/CD11b+ cells. The same 
labelling was done for primary microglia and both were then stained for Siglec-E. 
Both ex vivo and primary microglia showed low constitutive Siglec-E expression 
when compared to isotype matched control antibodies (Figure 3.1). In detail the 
median Siglec-E fluorescence intensity for ex vivo microglia was 133.67  40.74 and 
452.50  46.62 for primary microglia, respectively. 
Therefore, ex vivo isolated and primary microglia do both express Siglec-E. 
 
        
Figure 3.1: Expression of Siglec-E in ex vivo and primary microglia. CD45
low
/CD11b
+
 ex vivo and 
primary microglia were analysed for Siglec-E expression. Both cell types showed low Siglec-E 
expression on their surface. Representative data out of at least three independent experiments are 
shown. 
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3.2.2 Siglec-E transcription in microglia 
Primary microglia or the microglia line ESdM were stimulated for 24 hours with either 
LPS, IFN-, IFN- or TNF-. mRNA was isolated from primary microglia, the 
microglia line, spleenocytes and neurons. Spleenocytes are known to have high 
levels of Siglec-E and were used as a positive control whereas neurons are known to 
have no Siglec-E and were used as negative control (Zhang et al. 2004). 
 
   
Figure 3.2: Detection of Siglec-E mRNA in microglia by RT-PCR. Siglec-E transcripts were 
detected in unstimulated primary microglia and in the microglia line ESdM (unstim). Stimulation with 
LPS, IFN-, IFN- or TNF- did not alter the transcription level of Siglec-E. The house-keeping gene 
Gapdh was used as an internal loading control. Spleenocytes (spleen) are known to highly express 
Siglec-E and served as a positive control, in contrast neurons do not express Siglec-E. Representative 
data out of three independent experiments are shown. Control: reaction mix without cDNA. 
 
PCR of the transcribed cDNA clearly showed that primary microglia and the microglia 
line ESdM both transcribed Siglec-E (Figure 3.2). Upon stimulation there was no 
significant difference in the level of Siglec-E transcripts in primary microglia and the 
microglia line. As expected, the spleenocyte cDNA showed the highest transcription 
level of Siglec-E mRNA whereas the neuron cDNA had no Siglec-E transcripts.  
The outcome of the reverse transcription was further confirmed by quantitative real-
time PCR. This method enabled us to quantify changes in the Siglec-E transcription 
level upon stimulation when compared to unstimulated cells. The values were 
normalized to the house-keeping gene Gapdh. As seen before using RT-PCR, 
stimulation with the different cytokines IFN-, IFN-, TNF- or LPS for 24 hours did 
not result in any significant changes in the mRNA transcription levels of Siglec-E in 
the microglia line ESdM (Figure 3.3). 
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Figure 3.3: Quantitative real-time PCR of stimulated ESdM. Stimulation with LPS or the cytokines 
IFN-γ, IFN-α or TNF-α did not result in a significant change in the transcription levels of Siglec-E 
mRNA after 24 hours stimulation. Data was normalized to the gene Gapdh.  
 
In conclusion, primary microglia and the microglia line have a detectable level of 
Siglec-E mRNA of Siglec-E.  
 
3.2.3 Siglec-E expression in microglia upon stimulation 
After it was shown that the expression of Siglec-E can be detected in ex vivo, primary 
microglia and the transcription in the microglia line ESdM, the next step was to show 
Siglec-E expression on the cell surface of microglia. For this purpose primary 
microglia and ESdM were stimulated with LPS, IFN-, IFN-α or TNF-α for 24 hours 
and then Siglec-E quantified using flow cytometry.  
In primary microglia and ESdM, low Siglec-E expression was detected by flow 
cytometry in unstimulated cells. Upon stimulation with IFN-, primary microglia 
showed an upregulation of Siglec-E on their surface whereas the other cytokines and 
LPS had no effect on the Siglec-E expression level (Figure 3.4). In ESdM both IFN- 
and IFN- increased the Siglec-E expression levels on the cells, but not the other 
stimulants. 
In summary, only IFN- and IFN- had an impact on the expression level of Siglec-E 
in primary microglia and the microglia line. 
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Figure 3.4: Flow Cytometry analysis for Siglec-E expression upon stimulation. Siglec-E was 
detected on unstimulated (unstim) microglia at low levels. A 24 hour treatment with IFN- or -α 
slightly increased the expression of Siglec-E on the microglia line, while treatment with LPS or TNF-α 
showed no effect. Representative data out of three independent experiments are shown. unstim: 
unstimulated cells; isotype: isotype control antibody. 
 
3.3 Lentiviral overexpression and knock-down of Siglec-E in ESdM 
Since there are hardly any functional data about Siglec-E, one of the main goals was 
to achieve a basic understanding of the role Siglec-E plays in microglia. For this 
purpose a microglia line was transduced with lentiviral particles to overexpress or 
knock-down Siglec-E. After characterization of these modified cells they were used 
for further experiments. 
 
3.3.1 Lentiviral over-expression or knock-down of Siglec-E does not change 
the microglial phenotype 
 
3.3.1.1 Siglec-E overexpression and knock-down constructs 
Siglec-E was tagged with GFP under the control of the CMV promotor (abbreviated 
later as „SigE vector“). It was cloned into the pll3.7 vector with a PGK-neomycin 
selection gene in front of the Siglec-E related expression cassette. The 
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corresponding control was the empty vector containing only GFP (abbreviated as 
“control vector”).  
Constructs for lentiviral knock-down of the receptor Siglec-E in the microglia line 
were obtained from a knock-down library in a pLKO.1 backbone and were kindly 
provided by Prof. Veit Hornung, Bonn (shRNASigE1: TRCN0000094526, target 
sequence 5’-CCCAATTCGTAAAGCAGTGAA-3’, abbreviated as „shRNASigE1“; 
shRNASigE2: TRCN0000094527, target sequence 5’-GCCACAAATAACCCAA 
TTCGT-3', abbreviated as „shRNASigE2“).  
 
3.3.1.2 Confirmation of successful transduction of microglia 
After the transduction of the microglia line with lentiviral particles for either 
overexpression or knock-down of Siglec-E, the outcome of the procedure was 
confirmed by qRT-PCR and flow cytometry. 
The qRT-PCR results showed that after the transduction with lentiviral particles for 
Siglec-E overexpression the transcription level was increased when compared to 
untransduced cells and the control vector. In detail, the transcription was 48.45  
4.06-fold higher than untransduced cells (1.0  0.08; p = 2.2 x 10-5; p = 2.2 x 10-5 
compared to control vector). The control vector showed no significant change in 
Siglec-E mRNA levels (1.12  0.11-fold increase) when compared to untransduced 
microglia (Figure 3.5).  
The knock-down efficiency was analysed in comparison to untransduced microglia 
and microglia having received lentiviral particles of the non-targeting shRNA 
(“NTshRNA”) control construct. Both transductions with the lentiviral particles of the 
knock-down constructs resulted in a significant reduction in Siglec-E transcription in 
the microglia. Siglec-E mRNA levels were decreased from 1.0  0.07 in 
untransduced cells and 1.04  0.01-fold in NTshRNA (p = 1.4 x 10-11) microglia to 
0.14  0.01-fold (p = 2.0 x 10-11; p = xxx to NTshRNA) for shRNASigE1 and 0.15  
0.01-fold for shRNASigE2 (p = 2.2 x 10-11; p = 1.5 x 10-11 to NTshRNA).  
Therefore the modification for Siglec-E in the microglia line was proven on the 
transcriptional level for overexpression and knock-down of Siglec-E. 
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Figure 3.5: Siglec-E transcription level after lentiviral transduction. Microglia were transduced 
with lentiviral particles of vectors expressing either Siglec-E:GFP (SigE vector) or a control vector. 
Furthermore, lentiviral knock-down was performed by two different lentiviral short-hairpin constructs 
targeting Siglec-E (shRNASigE1; shRNASigE2) or a corresponding non-targeting control vector 
(NTshRNA). qRT-PCR confirmed the successful modification of the microglial line by showing an 
increase in Siglec-E cDNA levels after lentiviral overexpression of Siglec-E (left graph) or a reduction 
in gene transcript levels after knock-down of Siglec-E (right graph). Numbers were normalized to the 
house-keeping gene Gapdh.  
 
To analyse the effect of the lentiviral transduction on the protein level as well, flow 
cytometry with an antibody directed against Siglec-E was performed. The 
transduction with the particles of the overexpression vector led to much higher 
Siglec-E expression in the microglia compared to that in untransduced microglia and 
microglia which only received the control vector (Figure 3.6). In contrast, the viral 
particles of both knock-down constructs shRNASigE1 and shRNASigE2 showed a 
diminished Siglec-E surface protein level of the cells when compared to 
untransduced cells and microglia transduced with the NTshRNA. 
Thus, the expression level of Siglec-E was successfully modified in the microglia line. 
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Figure 3.6: Siglec-E surface expression level after lentiviral transduction. Flow cytometry 
confirmed modification of the microglial line. Lentiviral transduction with the construct for 
overexpression of Siglec-E (SigE vector) led to an increase in Siglec-E expression (upper graph) 
compared to untransduced and control vector microglia. Both knock-down vectors (shRNASigE1; 
shRNASigE2) resulted in a clear decrease of Siglec-E surface expression on microglia (lower graph) 
when compared to untransduced cells and microglia having received the NTshRNA viral particles. 
 
3.3.1.3 Lentiviral transduction does not change the microglial phenotype 
After the altered transcription and expression level of Siglec-E in the modified 
microglia line was confirmed, it had to be analysed if the lentiviral transduction 
caused any changes in the microglial phenotype. The microglia were analysed for 
changes in cytokine transcription and surface marker expression after successful 
lentiviral transduction. 
The transcription profile of IL-1, NOS2 and TNF- was analysed by qRT-PCR in the 
modified microglia and the corresponding control cell lines. As an internal control the 
gene Gapdh was used.  
For the Siglec-E overexpressing cells as well as for the Siglec-E knock-down cells, 
the transcription level of all the cytokines and surface markers analysed remained 
unchanged when compared to untransduced cells or the corresponding control 
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vector. In detail, for IL-1 the transcription level after lentiviral overexpression for 
Siglec-E remained quite stable with a non-significant fold increase from 1.0  0.32 
(untransduced cells) to 1.45  0.22 for the control vector and to 1.52  0.51 for 
Siglec-E overexpression (Figure 3.7).  
The same holds true for the knock-down vectors. In this case, the alteration was from 
1.0  0.23 (untransduced) or 1.23  0.38 (NTshRNA) to 0.87  0.47-fold 
(shRNASigE1) and 1.12  0.43 (shRNASigE2), respectively. For NOS2 the mRNA 
levels remained unchanged from 1.0  0.19 (untransduced) to a 1.38  0.37-fold 
change (control vector) and to a 0.9  0.3-fold change (SigE vector). The knock-down 
microglia showed stable transcription levels at a fold change of 1.28  0.35 
(shRNASigE1), 1.55  0.16 (shRNASigE2) and 1.2  0.43 (NTshRNA) when 
compared to untransduced cells (1.0  0.21). TNF- transcription levels for Siglec-E 
overexpressing microglia were not affected by the transduction procedure. They 
remained at a 1.15  0.24-fold change compared to 1.0  0.12 (untransduced) and 
1.05  0.07 (control vector). Similarly, TNF- mRNA levels in Siglec-E knock-down 
microglia were unaffected by lentiviral transduction. The fold change was from 1.0  
0.12 (untransduced) and 1.37  0.41 (NTshRNA) to 1.25  0.65 (shRNASigE1) and 
0.96  0.35 (shRNASigE2), respectively. 
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Figure 3.7: No change in cytokine transcription in modified microglia. The transduced microglia 
were analysed in regard to their inflammatory phenotype. They were analysed for IL-1, NOS2 and 
TNF- mRNA levels by qRT-PCR. Neither Siglec-E overexpressing microglia nor the Siglec-E knock-
down cells had any significant change in the transcription level of the cytokines. Data were normalized 
to the house-keeping gene Gapdh.  
 
In addition, a flow cytometry experiment was performed to display the surface marker 
expression profile of the modified microglia. The expression levels of CD11b, CD11c, 
CD18, CD31, CD34, CD45, CD80, CD86 and F4/80 were measured. CD31 and 
CD34 are markers of not fully differentiated cells and therefore no expression of 
these markers was expected. In contrast, the microglia line is known to express high 
levels of CD11b and CD45 on their surface. Overall the surface marker expression 
profile of the Siglec-E overexpressing microglia was comparable to that of 
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untransduced and control vector transduced cells (Figure 3.8a). The same holds true 
for both of the knock-down constructs shRNASigE1 (Figure 3.8b) and shRNASigE2 
(Figure 3.8c) when compared to the untransduced and NTshRNA microglia. 
In conclusion, the lentiviral transduction procedure did not alter the microglia 
phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See next page: 
Figure 3.8: Microglia surface marker expression profile remains unchanged after lentiviral 
transduction. After the transduction procedure, surface marker expression of the modified microglia 
was analysed. a The expression level of the surface markers was not influenced by overexpression of 
Siglec-E on microglia or by the control vector. b The construct shRNASigE1 showed a comparable 
expression profile to that of untransduced and NTshRNA microglia. c shRNASigE2 transduction did 
not affect marker expression levels on microglia. Representative data out of three independent 
experiments are shown.  
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3.4 Phagocytosis of neural debris by microglia 
Microglia are the phagocyting cells of the brain. They can phagocyte cellular debris 
and secrete anti-inflammatory cytokines. By this mechanism they prevent 
inflammatory processes caused by apoptotic cells and thereby help maintain a 
healthy environment for all the brain cells especially for the neurons in the CNS. 
Since this is one of the key functions of microglia, the modified microglia were 
analysed as to whether the introduced modifications in the expression level of Siglec-
E might influence this main characteristic. 
 
3.4.1 Siglec-E expression levels influence phagocytosis rate of microglia 
The modified microglia were challenged with neural debris and phagocytosis was 
analysed under the microscope. The merged images show overlays of microglia and 
neural debris indicating the event of phagocytosis.  
Microglia expressing GFP display a higher rate of phagocytosis of neural debris 
when compared to microglia overexpressing Siglec-E. In contrast, microglia having 
received the NTshRNA show less overlay events compared to microglia with a 
Siglec-E knock-down. When considering the number of phagocytosed neural debris 
particles per phagocytosing cell, microglia with a knock-down of Siglec-E seem to 
have a higher number of phagocytosed neural debris particles per phagocytosing cell 
compared to microglia, which had been transduced with the NTshRNA control 
(Figure 3.9).   
 
 
3. Results 50 
 
 
 
Figure 3.9: Phagocytosis of neural debris by modified microglia. Lentiviral transduced microglia 
with different expression levels of Siglec-E were challenged with neural debris. Phagocytosis of the 
neural debris was analysed. Siglec-E overexpressing microglia (SigE vector) showed less 
phagocytosis than their corresponding control (control vector). Siglec-E knock-down microglia 
(shRNASigE1; shRNASigE2) had more phagocytosis events when compared to their control 
(NTshRNA). Representative images out of three independent experiments are shown. Scale bar: 30 
µm. 
 
To prove that the neural debris was indeed in the microglia, three-dimensional 
reconstruction images were taken. The images showed that the neural debris was 
indeed inside the cells. The control lines (control vector; NTshRNA) demonstrated a 
comparable amount of phagocytosed neural debris, whereas Siglec-E 
overexpressing microglia had only few neural debris particles. Siglec-E knock-down 
microglia had the highest number of neural debris when compared to the other cells 
(Figure 3.10a).  
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Figure 3.10: Siglec-E overexpression prevents phagocytosis of neural debris. a Uptake of red 
fluorescent labelled neural debris (red) into microglia (green) was analysed by confocal microscopy 
and 3D-reconstruction. Microglial cells were lentiviral transduced with either the control vector, the 
Siglec-E over-expressing vector (SigE vector), the Siglec-E knock-down constructs (shRNASigE1; 
shRNASigE2) or the non-targeting vector (NTshRNA). Representative images out of three 
independent experiments are shown. Scale bar: 20 µm. b The phagocytosis rate of the microglia was 
quantified. Overexpression of Siglec-E on the cell surface led to a reduction in phagocytosis rate, 
while knock-down of Siglec-E increased the uptake of neural debris. 
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Quantification of neural debris uptake revealed that an overexpression of Siglec-E on 
the microglia resulted in a decrease in phagocytosis rate from 34.17  1.30 % 
(control vector; p = 1.65 x 10-8) down to 17.55  1.30 % of phagocytosing cells. On 
the contrary, knock-down of Siglec-E in the microglia line led to an increase in the 
uptake of neural debris. In detail, microglia transduced with the NTshRNA vector 
showed a phagocytosis rate of 31.0  0.06 % whereas cells being modified with 
shRNASigE1 lentiviral particles had a phagocytosis rate of 44.32  0.86 % 
(p = 6.93 x 10-7) and transduction with shRNASigE2 particles led to 44.03  0.71 % 
(p = 9.86 x 10-7) phagocytosis (Figure 3.10b). 
While Siglec-E overexpressing microglia showed a decreased phagocytosis rate, 
Siglec-E knock-down microglia had a higher phagocytosis rate. 
 
3.4.2 Siglec-E knock-down leads to an increase in superoxide production in 
microglia 
Phagocytosis is frequently associated with a burst of reactive oxygen species. As 
Siglec-E expression levels had an influence on the phagocytosis rate in microglia, it 
was of further interest whether Siglec-E has an impact on the production of reactive 
oxygen species as well.  
Microglia modified with the knock-down constructs shRNASigE1 and shRNASigE2 
displayed the highest fluorescence intensity for DHE ROS staining whereas microglia 
overexpressing Siglec-E (SigE vector) or microglia having been transduced with the 
non-targeting shRNA (NTshRNA) showed lower fluorescent intensities (Figure 
3.11a). Quantification of the fluorescence intensities showed that the increase in 
ROS production after addition of neural debris was strongest in microglia with the 
lowest Siglec-E expression levels (shRNASigE1; shRNASigE2). In detail, the mean 
fluorescence intensity increased from 1.38  0.03 for the NTshRNA microglia treated 
with neural debris to 2.25  0.19 for shRNASigE1 (p = 2.24 x 10-11) incubated with 
neural debris and to 2.44  0.21 for microglia modified by lentiviral particles of the 
construct shRNASigE2 stimulated with neural debris (p = 3.19 x 10-16). Microglia, 
which have been transduced with a control vector, only had a moderate increase of 
superoxide production after challenge with neural debris to 1.26  0.05. Siglec-E 
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overexpressing microglia did not even show a significant increase in ROS production 
after treatment with neural debris (0.98  0.11; Figure 3.11b). 
Since only the knock-down constructs led to a significant increase in ROS production 
after stimulation with neural debris, these cells were chosen for the scavenging 
experiments. While challenging microglia with neural debris, the addition of one of 
the free radical scavenger, SOD1 or trolox, led to comparable levels of ROS 
production as cells which received no neural debris (Figure 3.11c). In detail, ROS 
production after cultivation of NTshRNA microglia in the presence of neural debris 
was decreased from 1.35  0.06 to 0.72  0.10 (p = 1.6 x 10-5) with addition of SOD1 
and to 0.73  0.07 (p = 3.0 x 10-5) with trolox. For shRNASigE1 the reduction was 
from 2.13  0.07 to 0.79  0.09 (SOD1; p = 5.36 x 10-24) and to 0.72  0.10 (trolox; 
p = 2.86 x 10-26), respectively. The shRNASigE2 microglia showed a similar 
diminution of DHE staining intensity from 2.09  0.11 to 0.77  0.07 for SOD1 
(p = 2.89 x 10-23) and to 0.70  0.06 for incubation in the presence of the scavenger 
trolox (p = 1.58 x 10-25). 
Siglec-E has an impact on the microglial phagocytosis rate and the associated 
oxidative burst. This event can be rescued by addition of a scavenger like SOD1 or 
trolox.  
 
See next page: 
Figure 3.11: Siglec-E prevents the phagocytosis associated reactive oxygen burst after 
challenge with neural debris. a DHE staining of modified microglia. Siglec-E overexpressing vector 
(SigE vector), Siglec-E knock-down constructs (shRNASigE1; shRNASigE2), non-targeting vector 
(NTshRNA). Control vector, Siglec-E overexpressing microglia and NTshRNA microglia displayed a 
moderate increase in fluorescence intensity after stimulation with neural debris. In contrast, knock-
down microglia showed an increase of fluorescence intensity after challenge with neural debris. 
Representative images out of five independent experiments are shown. Scale bar: 30 µm. 
b Quantification of superoxide production in microglia after challenge with neural debris. Lack of 
Siglec-E on microglia led to increased levels of ROS production when compared with NTshRNA. 
c Analysis of superoxide levels in Siglec-E knock-down microglia challenged with neural debris in 
either the presence of SOD1 or trolox. Both scavengers were able to restore the elevated ROS 
production after knock-down of Siglec-E in microglia and treatment with neural debris back to the ROS 
production level of untreated cells. 
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To prove the outcome of the experiments with DHE, another method was used. 
Amplex Red is able to react with H2O2 to produce resorufin, which can be measured 
by a spectrofluorimeter. Cells were incubated with neural debris in suspension and 
H2O2 production was quantified by converting superoxide to H2O2 with SOD1. Similar 
to the DHE experiments, incubation with neural debris stimulated ROS production in 
microglia only about 1.1-fold in the control vector transduced microglia, whereas 
knock-down of Siglec-E resulted in a 2 to 3-fold increase in superoxide level (Figure 
3.12). In detail, production of 12.10  1.10 pmol H2O2 equivalents/min/mg protein in 
untreated control cells (NTshRNA) increased to 13.6  1.34 pmol H2O2 
equivalents/min/mg protein after addition of neural debris. In microglial cells with a 
knock down of Siglec-E by shRNASigE1 release of superoxide increased from 15.43 
 0.47 pmol H2O2 equivalents/min/mg protein to 32.39  0.39 pmol H2O2 
equivalents/min/mg protein following stimulation with neural debris (p = 1.89 x 10-26). 
A similar increase in superoxide production was observed in neural debris treated 
cells after knock down with shRNASigE1 (from 16.13  0.65 pmol H2O2 
equivalents/min/mg protein to 28.15  1.12 ; p = 1.16 x 10-15). 
Thus, the Amplex Red method confirmed the outcome of the DHE method. 
 
 
Figure 3.12: Siglec-E knock-down microglia have increased production of superoxide following 
incubation with neural debris. Quantification of superoxide production in microglia by a 
spectrofluorimeter. Siglec-E knock-down microglia had increased levels of ROS production when 
challenged with neural debris compared with NTshRNA. cells: addition of cells; catalase: addition of 
catalase to stop the reaction 
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3.4.3 Siglec-E overexpression reduces production of proinflammatory 
cytokines triggered by neural debris 
The next question was whether Siglec-E also plays a role in the production of 
proinflammatory cytokines triggered by the 16 hours treatment with neural debris.   
The transcriptional levels of IL-1 and TNF- were significantly increased after 
stimulation with neural debris in Siglec-E knock-down microglia compared to control 
cells (NTshRNA) that have been stimulated with neural debris, while there was no 
effect on the mRNA level of NOS2 (Figure 3.13). In detail, gene transcription of IL-1 
was increased from 10.0  0.13 to 17.42  2.26 after knock-down with shRNASigE1 
(p = 0.001) and to 16.56  1.10 after knock-down with shRNASigE2 (p = 0.003). The 
mRNA level of TNF- was increased from 9.07  1.39 to 14.21  0.73 after knock-
down with shRNASigE1 (p = 0.011) and to 15.27  1.15 after knock-down with 
shRNASigE2 (p = 0.001). Overexpression of Siglec-E had no significant effect on the 
gene transcription of proinflammatory mediators after neural debris challenge when 
compared to control cells (control vector).  
In summary, Siglec-E on microglia acted anti-inflammatory by preventing the 
production of the pro-inflammatory cytokines IL-1 and TNF- after 16 hours 
challenge with neural debris. 
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Figure 3.13: Siglec-E overexpressing microglia show diminished production of 
proinflammatory cytokines after treatment with neural debris. qRT-PCR to detect IL-1, TNF- 
and NOS2 transcription levels after 16 hours incubation of modified microglia with neural debris. 
Microglia with knock-down of Siglec-E (shRNASigE1; shRNASigE2) showed a significant increase in 
gene transcription of IL-1 and TNF- after incubation with neural debris compared to the control 
vector (NTshRNA). n.s. not significant. 
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3.5 Siglec-E:Fc fusion protein binding to primary cells  
It is known that Siglec-E can bind different linkages of sialic acid with a binding 
preference for 2-8 linked sialic acid to 2-6 and 2-3 linked sialic acid. Polysialic 
acid (PSA) is a polymer of 2-8 linked sialic acid, which can be found attached to the 
neural cell adhesion molecule (NCAM). A fusion protein of Siglec-E consisting of only 
the extracellular part of Siglec-E fused to a mouse immunoglobulin domain was used 
to investigate the binding behaviour of Siglec-E to polysialic acids chains in the 
glycocalyx of astrocytes and neurons. 
 
3.5.1 Siglec-E:Fc binds to neurons 
Primary neurons were either treated or untreated with sialidase to remove sialic acid 
from their cell surface. After the treatment, the fusion proteins Siglec-F:Fc and 
Siglec-E:Fc were applied to analyse their binding capacity. For Siglec-F:Fc it has 
been previously shown in our lab that it is capable of binding to neurons and that this 
feature is abrogated after treatment with sialidase (Linnartz et al. 2012a). Therefore it 
was used as a positive control for this experiment. 
Without sialidase treatment both fusion proteins Siglec-F:Fc and Siglec-E:Fc were 
able to bind sialic acid on the neuronal surface as indicated by the co-staining with 
the neurons (Figure 3.14). However, after the enzymatic removal of sialic acid from 
the neuronal glycocalyx none of the fusion proteins was binding to the neurons. 
Thus, sialic acid is a crucial factor in the neuronal glycocalyx to allow the binding of 
Siglec-F and Siglec-E to the cell surface. 
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Figure 3.14: Binding of Siglec-F:Fc and Siglec-E:Fc fusion protein to neurons. Neurons were 
either untreated or treated with sialidase to remove sialic acid from the cell surface. The removal of 
sialic acid resulted in a reduction of the binding capacity of Siglec-F:Fc and Siglec-E:Fc to neurons. 
Representative images out of three independent experiments are shown. Scale bar: 30 µm. 
 
3.5.2 Siglec-E:Fc binds to astrocytes and primary microglia 
Primary astrocytes or microglia were either untreated or treated with a combination of 
neuraminidase and EndoN for 2.5 hours to enzymatically remove sialic acid. 
Subsequently cells were cultured with a recombinant Siglec-E:Fc fusion protein for 
1 hour. The outcome was analysed by confocal microscopy. The analysis revealed 
that Siglec-E:Fc bound to primary astrocytes and microglia (Figure 3.15). Enzymatic 
removal of sialic acid residues by EndoN and neuraminidase treatment resulted in an 
abrogation of the binding capacity of Siglec-E:Fc to both cell types, indicating that 
sialic acid residues in the glycocalyx of the cells were needed for Siglec-E:Fc fusion 
protein to bind to the cells.  
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Figure 3.15: Siglec-E:Fc binds to primary astrocytes and microglia. The fusion protein Siglec-
E:Fc was cultured with astrocytes or primary microglia for 1 hour. Staining showed that Siglec-E:Fc 
was able to bind to astrocytes and primary microglia. Enzymatic removal of sialic acid led to a 
reduction in the binding capacity of the recombinant Siglec-E:Fc fusion protein. Representative images 
out of three independent experiments are shown. Scale bar: 30 µm. 
 
3.6 Co-culture of primary neurons and microglia 
After it had been proven that Siglec-E is indeed capable of binding to the neuronal 
glycocalyx in a sialic acid-dependent manner, the next point of interest was to 
investigate the impact of the modification in Siglec-E expression levels on microglia 
in a neuron-microglia co-culture system. For this purpose primary neurons and 
modified microglia of the microglia line were co-cultured for 48 hours. 
 
3.6.1 Siglec-E is neuroprotective in a neuron-microglia co-culture system 
Primary neurons were either untreated or treated with the enzyme sialidase to 
remove sialic acid from the cell surface. Following the treatment, the neurons were 
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co-cultured with microglia having different expression levels of Siglec-E on their 
surface for 48 hours. Cells were stained by immunocytochemistry and the change in 
relative neurite length was quantified. Overexpression of Siglec-E increased the 
relative neurite length while knock-down of Siglec-E reduced it (Figure 3.16a). In 
detail, the neurite length was increased from 100 %  9.97 % (control vector) to 
150 %  2.19 % following overexpression of Siglec-E on microglia (p = 1.07 x 10-13; 
Figure 3.16b). Siglec-E knock-down on microglia reduced the relative neurite length 
from 100 %  5.31 % (NTshRNA) to 70 %  1.45 % (shRNASigE1, p = 1.62 x 10-9) 
and to 69 %  1.2 % (shRNASigE2, p = 6.06 x 10-10). Enzymatic removal of the 
glycocalyx’s sialic acid abolished both of the effects and led to a reduction in the 
relative neurite length of the neurons in all the control conditions and the microglia 
with the modified Siglec-E expression level. 
To exclude side effects due to changes in the cell-cell ratio, the neuronal cell body 
density with respect to percentage in the co-culture system was quantified. The 
outcome clearly showed that there was no change in the neuronal cell body density 
for all the different settings in this experiment (Figure 3.16c). 
In conclusion, microglia were able to sense sialic acid in the neuronal glycocalyx by 
their Siglec-E receptors. Siglec-E overexpression on microglia led to an increase of 
the relative neurite length in the co-culture system whereas knock-down increased 
the cytotoxicity with respect to the neurons, resulting in a reduction of the relative 
neurite length. 
 
See next page: 
Figure 3.16: Siglec-E overexpressing microglia act neuroprotective in a neuron-microglia co-
culture system. a Neurons were co-cultured for 48 hours with microglia expressing different amounts 
of Siglec-E. In co-culture with Siglec-E overexpressing microglia, neurons seemed to have longer 
neurites, whereas in the presence of Siglec-E knock-down microglia, neurons had shorter neurites. 
Representative images without sialidase treatment out of three independent experiments are shown. 
Scale bar 30 µm. b Quantification of relative neurite length. Siglec-E overexpression led to an increase 
in relative neurite length whereas knock-down of Siglec-E caused a reduction in relative neurite length. 
After enzymatic removal of sialic acid the relative neurite length was significantly reduced when 
compared to untreated neurons. c Neuronal cell body density in relation to microglia was counted to 
exclude side effects due to changes in the cell-cell ratio. There was no significant difference in the 
neuronal cell body density.  
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3.6.2 Siglec-E exerts its neuroprotective effect by attenuation of reactive 
oxygen species release 
Primary neurons were co-cultured with modified microglia either in the presence or 
absence of 40 nM Trolox for 48 hours. Trolox is a vitamin E analogue, which is an 
antioxidant and capable of scavenging superoxide anions. After 48 hours cells were 
stained and analysed for their relative neurite length (Figure 3.17a). In the presence 
of the scavenger trolox, the relative neurite length of neurons in co-culture with 
Siglec-E knock-down microglia was restored to 97 %  2.91 % for knock-down with 
shRNASigE1 (NTshRNA 103 %  1.53 %), and 94 %  2.85 % for shRNASigE2 
(Figure 3.17b). In co-culture with Siglec-E overexpressing microglia the relative 
neurite length seemed to be unaffected by Trolox treatment. Quantification of the 
neuronal cell body density again showed that there was no change in the cell-cell 
ratio in the different experimental settings (Figure 3.17c). 
Thus, the cytotoxicity of Siglec-E knock-down microglia on the relative neurite length 
could be scavenged by addition of 40 nM Trolox in the co-culture system. This 
indicates that Siglec-E participates in the regulation of the microglial oxidative burst. 
 
 
 
 
 
See next page: 
Figure 3.17: Siglec-E exerts its neuroprotective effect by attenuating the production of reactive 
oxygen species. a Neurons were treated with 40 nM Trolox and then co-cultured for 48 hours with  
microglia expressing different levels of Siglec-E on their surface. The neurites of the neurons being co-
cultured with Siglec-E overexpressing microglia had the longest neurites. The other conditions (control 
vector, NTshRNA, shRNASigE1 and shRNASigE2) displayed comparable neurites lengths. 
Representative images with Trolox treatment out of three independent experiments are shown. Scale 
bar 30 µm. b Quantification of relative neurite length. The relative neurite length was restored after the 
treatment with 40 nM Trolox by which the release of ROS and their harmful effect was diminished. 
c Neuronal cell body density in relation to microglia was counted to exclude side effects due to 
changes in the cell-cell ratio. There was no significant difference in the neuronal cell body density.  
3. Results 64 
 
 
4. Discussion 65 
 
4. Discussion 
4.1 Siglecs in mouse and human  
The mouse Siglec family consists of nine members from which four belong to the 
common Siglecs (Siglec-1, Siglec-2, Siglec-4, Siglec-15) and five to the family of the 
CD33-related Siglecs (Siglec-3, Siglec-E, Siglec-F, Siglec-G, Siglec-H). Among them 
four have an ITIM and ITIM-like motifs in their cytoplasmic tail (Siglec-2, Siglec-E, 
Siglec-F, Siglec-G) whereas Siglec-3 has only an ITIM-like motif in the cytoplasmic 
domain (Pillai et al. 2011). Some Siglecs are expressed on a single cell type of the 
immune system, like Siglec-2/CD22 and Siglec-G, which are exclusively expressed 
on B cells, and Siglec-F, which is expressed solely on eosinophils. Others like 
Siglec-3 and Siglec-E can be found on a different set of cells of the myeloid line, for 
example Siglec-E can be found on neutrophils, monocytes and dendritic cells 
(Crocker et al. 2007). The present study now reveals that Siglec-E is transcribed and 
expressed in mouse microglia as well.  
In contrast, 15 Siglecs can be found in humans. The human common Siglecs have 
the same nomenclature as the mouse ones. The CD33-related Siglecs are Siglec-3, 
Siglec-5 to Siglec-16. Among the human Siglecs, ten have ITIM and ITIM-like motifs 
(Siglec-2, Siglec-3, Siglec-5 to Siglec-12) and three have just an ITIM-like motif 
(Siglec-14 to Siglec-16) (Pillai et al. 2011). The human Siglec-11 is another Siglec, 
which is expressed on microglia in the brain like Siglec-E (Hayakawa et al. 2005). A 
study showed that Siglec-11 is capable of interacting with the neuronal glycocalyx by 
recognizing 2-8-linked sialic acid and thereby prevents neurotoxic effects (Wang 
and Neumann 2010). But Siglec-11 has no homolog in the mouse system.  
Siglec-E is most similar in its sequence to the human Siglec-7, Siglec-8 and Siglec-9 
but in its expression profile Siglec-E mostly resembles Siglec-7 and Siglec-9. 
Siglec-E shows the same preference for 2-8-linked sialic acid like Siglec-7 or 
Siglec-11. However, there is no homolog for Siglec-E in the human system (Wang 
and Neumann 2010; Zhang et al. 2004). A study of gene expression profiles revealed 
that Siglec-11 and Siglec-E are not the only inhibitory Siglecs, which are expressed 
on microglia or macrophages. CD33/Siglec-3 expression can be found in spleen 
macrophages, Siglec-5 is transcribed in microglia, Siglec-1 is expressed in lung and 
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spleenic macrophages and Siglec-F can be found in lung macrophages (Gautier et 
al. 2012). Existing data now suggest that the leukocytes from the innate immune 
system have inhibitory Siglec receptors on their cell surface, which are able to sense 
the sialic acid caps in an intact glycocalyx and by this to distinguish between “self” 
and “non-self” (Varki 2011). Binding of a so-called “self”-ligand leads to the inhibition 
of an immune response via the ITIM counteracting an activating ITAM signal 
(Linnartz et al. 2010). 
Our data now suggest that Siglec-E is a receptor recognizing the intact glycocalyx of 
primary neurons and thereby identifies if the neuron is “healthy” or harmed. This 
function is in line with a previous study of Siglec-11 in a co-culture system with 
primary hippocampal neurons (Wang and Neumann 2010). The study found out that 
Siglec-11 had a neuroprotective function as long as the neurons had sialic acid in the 
glycocalyx. Enzymatic removal of the sialic acid cap resulted in a loss of the 
neuroprotective function of Siglec-11 in microglia. According to our data, Siglec-E 
seems not to belong to either of the microglia receptor groups, which recognize 
pathogen-associated molecular patterns (PAMPs), or to the group, which senses 
danger-associated molecular patterns (DAMPs). Siglec-E rather belongs to a type of 
receptor, which recognizes self-associated molecular patterns (SAMPs) like the sialic 
acid cap (Varki 2011). A study demonstrated that Siglec-E has a preference for the 
sialic acid N-acetyl-neuraminic acid (Redelinghuys et al. 2011). By this property 
Siglec-E on microglia is well adapted for recognizing the microenvironment in the 
mouse brain as the murine brain solely expresses N-acetyl-neuraminic acid (Varki 
and Schauer 2009). 
 
4.2 Siglec-E has anti-inflammatory properties 
Siglec-E has been shown before to play a role in the regulation of the immune 
response. Following stimulation with LPS or other TLR agonists, Siglec-E on 
macrophages was upregulated in a MyD88-dependent mechanism and 
phosphorylated. Cross-linking of Siglec-E on macrophages led to a significantly 
decreased production of the NF-B-dependent cytokines TNF- and IL-6. Further, 
the overexpression of Siglec-E inhibited the TIR domain containing adaptor inducing 
IFN-, (TRIF)-driven IFN- and RANTES whereas the knock-down displayed an 
increase in RANTES production. Therefore, Siglec-E seemed to take part in the 
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control of the antiviral response to TLRs by helping to maintain the cytokine balance 
after infection (Boyd et al. 2009). 
In a more recent publication Siglec-E was demonstrated to be crucial for the 
regulation of neutrophil recruitment to the lung under pathological conditions. A 
knock-out mouse model showed a more rapid and greater migration of neutrophils 
and macrophages in the airways in an aerosolised LPS-induced acute lung airway 
inflammation model. The same holds true for stimulation with zymosan, 
demonstrating that this effect was not exclusively for LPS but it was shown to be 
selective for the lung. Additional investigations revealed that Siglec-E is a negative 
regulator of the integrin CD11b-dependent adhesive function by suppressing the 
phosphorylation and thereby the activation of the Src family kinase Syk and p38 MAP 
kinase (McMillan et al. 2013). 
In line with the former observations, the stimulation with neural debris led in this 
study to elevated levels of the proinflammatory cytokines IL-1 and TNF- in 
Siglec-E knocked-down microglia and to decreased levels in microglia 
overexpressing Siglec-E. This immunoregulatory property of Siglecs under 
pathological conditions is not unknown in literature. Thus, CD22 has been 
demonstrated to be strongly expressed in gastrointestinal lamina propria eosinophils 
in the upper gastrointestinal tract with highest amounts in the jejunum. 
Overexpression of IL-5 was accompanied by downregulation of CD22 expression. In 
a state of gastrointestinal inflammation CD22 expression on eosinophils was reduced 
as well. CD22 knock-out mice showed a higher percentage of eosinophils among 
total lamina propria cells. This negative correlation of CD22 expression levels and the 
percentage of eosinophils in the intestines suggests an important role of CD22 in the 
regulation of tissue eosinophilia in the gastrointestinal tract (Wen et al. 2011). A 
similar property was detected for the murine Siglec-F, which is known to be 
expressed on eosinophils (Zhang et al. 2007). Chronic challenge with ovalbumin 
(OVA) led to an increase in bronchoalveolar lavage (BAL), peribronchial, bone 
marrow and peripheral blood eosinophils in Siglec-F deficient mice. Additionally, the 
OVA treated Siglec-F deficient mice had elevated levels of airway mucus, a higher 
amount of lung collagen, increased smooth muscle peribronchial thickness and the 
area stained for trichome was increased as well suggesting an increase in 
peribronchial fibrosis. Furthermore, mice lacking Siglec-F had more peribronchial 
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cells positive for TGF-1 and levels of eotaxin-1 and RANTES were elevated as well. 
Treatment with the cytokines IL-4 and IL-13 increased the level of Siglec-F ligands in 
WT mice. Summarizing, Siglec-F deficient mice had a stronger immune response 
and displayed altered cytokines levels in favour of pro-inflammatory cytokines similar 
to that demonstrated for the knock-down of Siglec-E in microglia. Taken together, 
these data illustrated once more the importance of Siglec receptors in maintaining 
the balance in the inflammatory response (Cho et al. 2010). 
For the human receptor CD33, which is expressed on peripheral human blood 
monocytes, the release of high levels of the proinflammatory cytokines IL-1, IL-8 
and TNF- was triggered by the challenge with a specific monoclonal antibody 
directed to CD33. The same happened through specific gene silencing of CD33. 
Activation of monocytes led to a downregulation of CD33, suggesting that CD33 has 
repressive properties on human monocytes (Lajaunias et al. 2005).   
Siglec-9 on immature dendritic cells, the human orthologue to Siglec-E, was shown 
to be capable of binding to tumour-produced mucins. Treatment with LPS in the 
presence of tumour mucins or treatment with an anti-Siglec-9 antibody resulted in a 
reduced production of IL-12 (Ohta et al. 2010). In another study with macrophages 
overexpressing Siglec-9, the stimulation with LPS or peptidoglycan only led to 
moderate levels of TNF- production whereas control macrophages reacted with a 
high amount of TNF- production to stimulation of TLRs. The same held true for IL-6 
and IFN- upon stimulation with either LPS or peptidoglycan. Mutations in the ITIM 
motifs of Siglec-9 abolished this effect. In contrast, the expression levels of the anti-
inflammatory cytokine IL-10 induced by TLRs were reduced in Siglec-9 
overexpressing macrophages. In the same study it was found out that Siglec-5 had 
similar effects when overexpressed on macrophages after stimulation with TLR 
agonists, IL-10 production was upregulated whereas TNF- production was 
diminished (Ando et al. 2008). This data is in line with the altered cytokine expression 
levels of stimulated microglia expressing different amounts of Siglec-E on their cell 
surface. 
Altogether, the data of the present study once more proves that ITIM-bearing Siglecs 
like Siglec-E play an important role in the regulation of the immune response to 
different threats such as the stimulation with neural debris. It is important for a 
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healthy microenvironment in the brain that apoptotic cells and debris are removed 
without over-activation of the immune system. Over-activation could lead to the 
overproduction of pro-inflammatory cytokines what in the end could damage the 
neurons in the CNS. The Siglec-E overexpression and knock-down approach on 
microglia showed that Siglec-E is a member of this tightly regulated system to keep a 
balanced cytokine level in the brain to ensure its functionality. This was demonstrated 
by stimulation with neural debris and the quantification of cytokine levels. The data of 
this study suggest that Siglec-E exerts its inhibitory function by negative regulation of 
pro-inflammatory cytokines like IL-1 and TNF- to prevent an over-activation of the 
immune response.  
 
4.3 Siglec-E is a regulator of phagocytosis and the associated 
oxidative burst 
This study shows that Siglec-E overexpression on microglia led to a decreased 
phagocytosis rate of neural debris and attenuation of the associated oxidative burst. 
In contrast, knock-down of microglial Siglec-E resulted in an increased phagocytosis 
rate of neural debris and higher production of superoxide. 
One of the main characteristics of microglia is phagocytosis of either pathogens or of 
cells that underwent apoptosis and cellular debris during development and in 
pathology and regeneration. Microglia are assumed to remove synapses in the 
developing brain and take part in neuronal pruning in the postnatal brain (Stevens et 
al. 2007). In neurodegenerative diseases like Alzheimer’s disease (AD) microglia 
clearance is of great importance as well. Microglia take up the soluble and fibrillar 
amyloid-beta, which is harmful for the neurons in the brain by pinocytosis or 
phagocytosis (Lee and Landreth 2010). Apoptotic cells attract microglia by displaying 
different signals. One prominent so-called “eat-me” signal is phosphatidylserine. 
Phosphatidylserine is transferred from the inner leaflet of the cell membrane to the 
outer leaflet by scramblases and flippases and serves as a signal for the microglia to 
find apoptotic cells (Ravichandran 2003; Ravichandran and Lorenz 2007).  
Changes in the glycocalyx can serve as a signal for phagocytosis as well. The 
induction of apoptosis in lymphoblasts led to a decrease of sialic acids on the cell 
surface (Meesmann et al. 2010). This process increased the binding of sialic acid 
4. Discussion 70 
 
binding plant lectins to the apoptotic cell-derived membranes and the subsequent 
engulfment by monocyte-derived phagocytes. Furthermore, a sialidase treatment of 
apoptotic cells increased the uptake compared to untreated cells. Even the 
incubation of neuraminidase treated viable lymphoblasts with monocyte-derived 
phagocytes led to an engulfment of the lymphoblasts. Therefore, the glycosylation 
status of a cell can act as a signal for phagocytes (Meesmann et al. 2010).  
The importance of ITAM and ITIM-signalling like from the Siglec receptors and their 
involvement in immune processes like phagocytosis was shown in model organisms 
like Caenorhabditis elegans and Drosophila melanogaster. A study in Caenorhabditis 
elegans showed that the receptor CED-1 is an important component in the 
engulfment of apoptotic cells (Zhou et al. 2001). The mechanism, which lies behind, 
is crucial for the uptake of necrotic cells, developmentally pruned axons and 
dendrites. The CED-1 orthologue in Drosophila is Draper. The phosphorylation of 
Draper was increased by a kinase from Src kinase family, the same kinase family 
that phosphorylates the ITAMs and ITIMs of Siglecs. This phosphorylation step was 
essential for glial phagocytic activity. Phosphorylated Draper associated with the 
tyrosine kinase Shark, which is similar to the mammalian Syk kinase, through an 
ITAM motif in the intracellular domain (Ziegenfuss et al. 2008). The activity of Shark 
was required for Draper-mediated signalling like recruitment of glial membranes to 
damaged neurons and the phagocytosis of axonal debris and neuronal corpses by 
glia (Ziegenfuss et al. 2008). A follow-up study found out that in Drosophila there are 
different splice variants of Draper (Logan et al. 2012). The draper-I isoform seemed 
to be necessary for phagocytosis of axonal debris and is expressed in embryos, 
larval brains and larval body wall tissue whereas the Draper-II isoform is solely 
expressed in adults. Isoform-I is the only splice variant harbouring an ITAM sequence 
in its intracellular part. In contrast, the Draper-II isoform contains an ITIM sequence in 
its intracellular part. Overexpression of splice variant II resulted in a complete block 
of glial clearance function. Furthermore Logan and colleagues discovered that the 
ITIM-bearing isoform-II associates with Corkscrew, the Drosophila homolog of 
vertebrate SHP-1 and SHP-2. Taken together, they proposed a model where 
Draper-II and Corkscrew inhibit glial engulfment activity by diminishing the activity of 
Draper-I and its signalling effectors like Shark by dephosphorylation (Logan et al. 
2012). This present study nicely shows that the same mechanism is conserved in 
Siglec signalling. ITIM-bearing Siglecs like Siglec-E counter-regulate the activatory 
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signals from ITAMs resulting in the inhibition of processes like phagocytosis, as was 
shown for Siglec-E overexpression on microglia in this study. Like ITIM-bearing 
Siglecs the isoform-II associated with a homolog of SHP-1 or SHP-2 to exert its 
inhibitory function. 
Other examples for the counter-regulation of an ITAM and an ITIM motif are the 
human receptors FcRIIA and FcRIIB. The ITIM receptor FcRIIB was shown to 
inhibit the FcR-mediated phagocytic pathways (Huang et al. 2003). Clustering of the 
human FcRIIA and the receptor FcRIIB led to a reduction in the efficiency of 
FcRIIA-mediated phagocytosis of IgG-coated erythrocytes up to 50 %. Co-
transfection of FcRIIB and the phosphatases SHP-1 or SHIP-1 further amplified this 
effect up to 85 % of phagocytosis inhibition. Transfection of FcRIIA with one of the 
phosphatases was capable of decreasing the phagocytosis rate even in the absence 
of FcRIIB by more than 50 %. In contrast, the overexpression of Syk kinase 
enhances phagocytosis in transfected epithelial cells (Huang et al. 2003). Like 
Siglec-E, FcRIIB decreased the phagocytosis rate by counteracting the activating 
signal of the FcRIIA. The association with SHP-1 or SHIP-1 was important as known 
for the ITIM-bearing Siglec receptors.  
The ITIM bearing human Siglec-5 and the mouse Siglec-1/Sn have been shown to be 
capable of binding to sialylated bacteria (Jones et al. 2003). The difference in the 
binding of Siglec-5 to non-sialylated or sialylated bacteria was 30- and 10-fold for two 
Neisseria meningitides strains. Significantly larger numbers of bacteria were taken up 
when they were sialylated. This effect could be inhibited by a Siglec-5 blocking 
antibody. When the uptake of bacteria of wild-type versus macrophages from Sn-
deficient mice was compared, the wild-type macrophages displayed an enhanced 
uptake of sialylated bacteria over a 30 minutes time course. In conclusion, this 
demonstrates that Siglecs can interact with sialylated pathogens and are able to 
engulf them (Jones et al. 2003). 
Thus, in line with these studies, the present experimental results suggest, that the 
microglial ITIM-containing receptor Siglec-E is a negative regulator of phagocytosis 
of microglia probably by counteracting an activatory ITAM signalling receptor and by 
recognition of the sialylation status of a cell. The removal of sialic acid was a 
triggering factor as seen in the co-culture approach with primary hippocampal 
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neurons. Mimicking the state of apoptotic or damaged cells by removal of sialic acid 
resulted in a decrease of the relative neurite length, which was mediated by the 
microglia. The amount of the decrease in the relative neurite length was dependent 
on the level of Siglec-E expression on the microglia. Similar to the Draper isoform II 
and FcRIIB, Siglec-E seemed to have a negative regulating function in the context of 
phagocytosis. Overexpression of Siglec-E resulted in a diminished phagocytosis rate 
of neural debris whereas the knock-down of Siglec-E on microglia led to an increased 
phagocytosis rate. The outcome of the knock-down approach suggests that if the 
inhibitory counterpart of the ITAM-ITIM-regulation is missing, an over-activation of the 
immune response could be the consequence like the one which was seen by the 
increase in the phagocytosis rate.  
 
Associated with phagocytosis is the production of reactive oxygen species. In 
neutrophils and macrophages, double-knock-out of DAP12 and FcR resulted in the 
lack of the ability to mediate the integrin induced respiratory burst by the ITAM-Syk 
pathway (Mocsai et al. 2006). The ITAM-Syk pathway is initiated by the ITAM-
bearing receptor DAP12 and FcR and signals via the Vav family of Rho guanine 
nucleotide exchange factors. This leads to the activation of the NADPH oxidase 
(NOX2) complex and production of reactive oxygen species (Graham et al. 2007). 
Siglecs bearing an inhibitory ITIM motif are thought to counteract the activatory 
signals by ITIM receptors like DAP12, suggesting an involvement on the regulation of 
the NOX2 complex. 
In another approach the participation of SHP-1 in the regulation of superoxide 
formation was investigated. SHP-1 is recruited by phosphorylated Siglec-E to 
counteract activatory signals of ITAM receptors. In the study by Krotz and colleagues 
blocking of SHP-1 in endothelial cells by distinct mechanisms resulted in increased 
basal superoxide release. The same held true for knock-down of SHP-1 with RNA 
interference. This effect was abolished by a nicotinamide adenine dinucleotide 
(phosphate) (NAD(P)H)-oxidase inhibitor and by a phosphatidyl-inositol-3-kinase 
(PI3K) inhibitor, suggesting that SHP-1 negatively regulates PI3K followed by 
attenuation of NAD(P)H-oxidase-dependent superoxide production (Krotz et al. 
2005).  
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The importance of ITAM-Syk and therefore counter-regulating ITIM receptors in ROS 
production has been exemplified by numerous studies. The C-type lectin Dectin-2 is 
crucial for NF-B activation and anti-fungal immune response. Silencing of Dectin-2 
or Syk had the consequence that THP-1 macrophages stimulated with swollen 
conidia of the fungus Aspergillus fumigatus were no more capable to react with a 
respiratory burst, which was seen for control THP-1 cells. Treatment with a Syk 
inhibitor resulted in the same outcome in WT macrophages demonstrating the 
essential role Syk plays in the ROS production mediated by Dectin-2 in response to a 
fungus infection (Sun et al. 2013). 
Another research group took a closer look at the mechanism lying behind the Syk-
pathway and the respiratory burst. Two different phases of the production of ROS 
could be identified. In platelets the first initial phase seemed to be independent of the 
Syk-pathway whereas the second phase involved the Syk-pathway. Furthermore, a 
blocking antibody of the ITAM receptor FcRIIa was able to abolish the FcRIIa-
induced ROS production in platelets indicating that the respiratory burst in platelets 
was dependent on the interaction with FcRIIa. ITIM receptors like Siglec-E could 
have a similar effect on ROS production as the overexpression and knock-down 
studies with Siglec-E showed. Overexpression of Siglec-E and thus the inhibitory 
stimulus for the activating ITAM-Syk pathway led to a remarkable decrease in ROS 
production. The platelet-specific collagen receptor GPVI/FcR is known to trigger 
ROS production in platelets. Generation of ROS induced by agonists of the receptor 
GPVI could be inhibited by a Syk inhibitor. In contrast, co-treatment with a GPVI and 
a FcRIIa agonist increased ROS production, which in turn was inhibited by the same 
Syk inhibitor. In summary, ROS generation in platelets could be induced by either 
GPVI/FcR or FcRIIa agonists but both are involved in the ITAM-Syk-pathway 
(Arthur et al. 2012), which could be regulated by receptors with an ITIM sequence. 
Hyperglycaemic conditions were shown to down-regulate CD33/Siglec-3 expression 
on primary human monocytes. This went along with an increase in the expression of 
proinflammatory cytokines like TNF-, which is in line with the results of the Siglec-E 
knock-down in microglia, showing elevated level of proinflammatory cytokines like 
IL-1 and TNF-. Treatment with the antioxidant -tocopherol reversed the down-
regulation of CD33 and the elevated TNF- production, suggesting a mechanism by 
which ROS generation is induced by high glucose concentrations and the 
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subsequent down-regulation of CD33 linking ROS production to CD33 expression 
levels (Gonzalez et al. 2012). In microglia the level of Siglec-E expression could be 
linked to the amount of ROS production as well. Knock-down of Siglec-E had similar 
results like the down-regulation of CD33/Siglec-3 namely elevated ROS production 
and increased release of proinflammatory cytokines. 
The CD22/Siglec-2 blocking antibody HB22.7 was recently applied in a study with 
Bortezomib treated lymphoma cells. Bortezomib is a proteasome inhibitor with anti-
lymphoma properties exerting its influence by generation of ROS and by induction of 
apoptosis. A sequential treatment of lymphoma cells with HB22.7 and Bortezomib 
reduced the number of viable cells by about 95 % and increased ROS production by   
more than 40 %, suggesting a synergistic cytotoxic effect via raised apoptosis and 
ROS production. This links the blocking of another Siglec to an increase in ROS 
production (Martin et al. 2011) like it was shown for Siglec-E in this study. 
Siglec-8 sharing a high sequence homology with Siglec-E is known to induce 
apoptosis in eosinophils via caspase-8 and/or caspase-9 (Nutku et al. 2003). Cross-
linking of Siglec-8 triggered caspase-3, caspase-8 and caspase-9 cleavage and led 
to an increase in annexin-V staining. Caspase inhibitors reduced Siglec-8-induced 
apoptosis in eosinophils. Additionally, Siglec-8 cross-linking resulted in mitochondrial 
dissipation, which is a characteristic of apoptosis. An inhibitor of ROS production was 
capable of completely inhibiting Siglec-8-mediated apoptosis and the associated 
mitochondria dissipation, indicating that ROS production is indispensable for 
Siglec-8-triggered apoptosis and precedes mitochondrial injury (Nutku et al. 2005). 
These results are in line with the analysis of ROS production in microglia with knock-
down of Siglec-E, which had higher ROS production than control cells. This effect 
could be reversed by addition of a scavenger like SOD1 or trolox. Additionally, in the 
co-culture approach of neurons with microglia, trolox was able to abolish the 
neurotoxic effect of Siglec-E knock-down microglia and restore the relative neurite 
length back to control levels.  
Concluding, the ITAM-Syk pathway seems to be of great importance for the initiation 
of ROS production in various cell types. Inhibition or knock-down of either Syk or a 
component bearing an ITAM sequence like the receptor DAP12 leads to a diminished 
respiratory burst. That Siglecs can indeed be linked to the respiratory burst was 
proven by the studies with CD33/Siglec-3, CD22/Siglec-2 and Siglec-8 (Gonzalez et 
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al. 2012; Martin et al. 2011; Nutku et al. 2005). As Siglec-E is an ITIM-containing 
receptor, which counter-balances activatory signals from ITAM receptors, it is not 
surprising to see that overexpression of Siglec-E on microglia resulted in a strongly 
reduced level of ROS whereas the knock-down of the inhibiting receptor Siglec-E led 
to an overproduction of ROS. Another indication for the involvement of Siglec-E in 
ROS production is that the elevated ROS production after knock-down of Siglec-E on 
microglia and treatment with neural debris could be rescued by addition of either the 
scavenger trolox or SOD1 to the system. This suggests, that for the knock-down of 
Siglec-E on microglia, the regulating part of this mechanism was missing, as was 
also shown in a study with SHP-1, leading to the increased amount of ROS 
production (Krotz et al. 2005).  
 
4.4 Microglial Siglec-E has neuroprotective properties in co-culture 
with neurons 
Experiments with a Siglec-E:Fc fusion protein demonstrated that Siglec-E binds to 
ligands on neurons, astrocytes and primary microglia. Overexpression of Siglec-E on 
microglia led to an increase in relative neurite length in a co-culture system indicating 
a neuroprotective function of Siglec-E in the co-culture system whereas knock-down 
of Siglec-E on microglia resulted in a diminished relative neurite length, arguing for a 
neurotoxic influence. Upon removal of sialic acid the binding capacity as well as the 
neuroprotective effect was abolished, demonstrating that the trans interaction with its 
ligands on the neurons was needed for Siglec-E to exert neuroprotection. Strikingly, 
co-culture of Siglec-E knock-down microglia and neurons in the presence of the ROS 
scavenger trolox reversed the neurotoxic effect, demonstrating that the neurotoxic 
effect was mediated via ROS. Thus, the data of this study suggest that microglial 
Siglec-E has neuroprotective properties by preventing ROS production. 
A similar effect was shown for murine microglia being modified to express human 
Siglec-11. Transduction of microglia with human Siglec-11 resulted in an elevation of 
relative neurite length and a higher neuronal cell body density in a co-culture system 
with neurons pointing to an alleviation of microglial neurotoxicity (Wang and 
Neumann 2010). 
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The idea of microglia playing an important role in brain homeostasis is not new. They 
can either be beneficial and neuroprotective or detrimental and neurotoxic. The 
frontier between the two is narrow since acute neuroinflammation can be necessary 
to clear a site of injury and minimize further injury but chronic neuroinflammation can 
be harmful by promoting neurodegenerative diseases like AD, Parkinson’s disease 
(PD) and amyotrophic lateral sclerosis (ALS). Activation of microglia in response to a 
threat includes phagocytosis (Napoli and Neumann 2009), antigen processing and 
presentation (Aloisi 2001), release of pro- and anti-inflammatory cytokines and of 
neurotoxic and neurotrophic factors (Walter and Neumann 2009).  
Microglia are the main source of the proinflammatory cytokine TNF- in the brain 
(Sawada et al. 1989). That TNF- can be harmful in neuropathogenesis has been 
shown before (Abo-Ouf et al. 2013). Rodriguez and colleagues used either the anti-
inflammatory agent minocycline or prednisolone or a combination of minocycline and 
prednisolone to treat the 6-hydroxydopamine hamster model. The treatment led to 
reduced levels of TNF- and iNOS, which resulted in better recovery of dopaminergic 
neurons after the neurotoxic stimulus (Rodriguez et al. 2013). In a co-culture system 
of neurons and p38-deficient microglia neurons were protected against LPS-
induced synaptic loss, neurite degeneration and neuronal death. The p38-deficient 
microglia produced decreased levels of TNF-. Strikingly, addition of TNF- to the 
system re-established LPS-induced neuron damage. Neutralization of TNF- in a co-
culture system with wildtype microglia prevented neuron damage. This demonstrates 
once more that microglia are the key mediators of LPS-induced neuronal and 
synaptic dysfunction partially through upregulation of TNF- (Xing et al. 2011). 
Another study used the immunosuppressive antibiotic rifampicin in co-culture of 
microglia and neurons. Stimulation of microglia with rifampicin led to reduced release 
of iNOS, TNF-, IL-1 and less production of NO. This resulted in reduced 
neurotoxicity and improved neuron survival (Bi et al. 2011). Fluoxetine is a selective 
serotonin re-uptake inhibitor. In a rat neuron-glia culture, fluoxetine was capable of 
attenuating LPS-induced chronic neurodegeneration as it inhibited activation of 
microglia and their release of proinflammatory cytokines like TNF- and IL-1 and 
the neurotoxic factors NO and ROS. Thereby, fluoxetine exerted a neuroprotective 
effect by preventing microglial neurotoxicity (Zhang et al. 2012). The Siglec-E 
expression level on microglia influenced the production of TNF- and IL-1 following 
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stimulation with neural debris. As the results of the before mentioned studies 
revealed, the release of cytokines like TNF- needs a tight control. Therefore, it can 
be assumed that Siglec-E is a regulator of the production of cytokines and thereby 
helps to prevent overproduction of proinflammatory cytokines, which could become 
harmful if not tightly regulated. That IL-1 is another cytokine with devastating 
potential like TNF- was shown in other studies. Ghrelin is a compound, which 
displayed neuroprotective properties in a PD model (Moon et al. 2009). An inducible 
IL-1-overexpressing mouse model showed a significant increase in tau 
phosphorylation and a fourfold to sixfold increase in microglia associating with 
plaques. The microglia at the site of injury seemed more activated (Ghosh et al. 
2013). Long-lasting expression of TNF- in the substantia nigra caused death of 
dopaminergic neurons, irreversible akinesia and microglia activation (De Lella 
Ezcurra et al. 2010).  
That no activation of microglia can be beneficial was demonstrated by a study where 
it was shown, that when there is no activation of microglia in the substantia nigra 
there is no activation of the NADPH oxidase, no ROS production and no production 
of proinflammatory cytokines and that this was advantageous for the dopaminergic 
neurons in the substantia nigra (Chung et al. 2012). Another study showed, that 
application of a free radical scavenger like SOD1 can be protective for dopaminergic 
neurons (Zhang et al. 2009). The study at hand demonstrated the neurotoxic effect of 
microglia using a knock-down of Siglec-E for neurons and showed that this effect 
was mediated by ROS since it could be reversed by the scavenger trolox. These 
results provide new insights to the impact of the Siglec-E expression level in 
microglia for ROS production and thereby its role for determining a neuroprotective or 
neurotoxic phenotype. 
In conclusion, activation of microglia is essential to clear a site of injury. This process 
involves release of cytokines and neurotrophic factors. On the other hand, the 
activation of microglia can become harmful to neurons when this event is not tightly 
regulated by counter-balancing mechanisms. Siglec-E seems to be part of the 
mechanism by which the immune response is regulated by microglia as 
overexpression led to reduced release of pro-inflammatory cytokines and a 
diminished production of free radicals. In a co-culture system, this beneficial effect 
could be demonstrated by an increase in relative neurite length after overexpression 
4. Discussion 78 
 
of Siglec-E on microglia, suggesting that Siglec-E has neuroprotective properties. 
The glycosylation pattern of the neurons was important to mediate the inhibitory 
effect of Siglec-E serving as a signal for the microglia to detect the healthy state of 
the neurons. 
The outcome of this study could be of great importance for diseases that are 
accompanied by chronic inflammation like AD, PD or ALS as the chronic activation of 
microglia promotes the course of the diseases. For CD33/Siglec-3 it was shown that 
a specific CD33/Siglec-3 SNP in AD patients, which was correlated with higher 
expression of CD33 on microglia, was associated with an increase of insoluble A42 
levels and amyloid plaque load. Inactivation of CD33/Siglec-3 enhanced the uptake 
of amyloid beta whereas increase in CD33/Siglec-3 levels inhibited the uptake of 
amyloid beta by microglia (Griciuc et al. 2013). Siglec-E belongs to the CD33-related 
Siglecs and is expressed on microglia in the brain. As shown by this study, Siglec-E 
takes part in the regulation of microglia activity by inhibiting the release of pro-
inflammatory cytokines like TNF- and IL-1 and diminishes phagocytosis and the 
associated production of reactive oxygen species. Therefore, Siglec-E is likely to be 
another Siglec that associates with neurodegenerative diseases and may play an 
important role in the immune response. Further study in the context of 
neurodegenerative diseases might thus be interesting, since Siglec-E appears to be 
a Siglec with neuroprotective properties.  
 
4.5 Outlook 
The present study shows that Siglec-E is a murine Siglec with immunomodulatory 
properties on microglia. Through the influence on the transcription level of 
proinflammatory cytokines and the production of ROS following stimulation, the 
expression level of Siglec-E on microglia seems to be crucial for the phenotype. In a 
co-culture system with neurons, the expression level of Siglec-E determined if the 
microglia were neuroprotective or neurotoxic. The sialic acid cap on the glycocalyx of 
the neurons was important to mediate the binding of Siglec-E. 
As this study provides solely in vitro data, the next interesting step would be to have 
a look into the in vivo situation. A study with Siglec-E knock-out mice already 
demonstrated that Siglec-E is crucial for the regulation of neutrophil recruitment in 
the lung (McMillan et al. 2013). But the impact of the Siglec-E knock-out on microglia 
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in the brain remains unknown so far. Further insights could be gained by analysing 
the influence of a Siglec-E overexpression on a neuroinflammatory disease model 
like experimental autoimmune disease (EAE) for Multiple Sclerosis to see, for 
example, whether pro-inflammatory cytokines are downregulated and whether the 
disease progression is reduced to a slower proceeding paralysis. Since Siglec-E 
overexpression was shown to lead to a more anti-inflammatory phenotype of 
microglia, a Siglec-E overexpressing mouse model might influence the disease 
progression to a milder disease course. 
The level of ROS production by microglia was affected by modulation of Siglec-E 
expression. ALS is a disease, which is linked to elevated ROS production and 
frequently associated with a mutation in SOD1. The NADPH oxidase is a source of 
ROS and was shown to be regulated by SOD1. This regulation is defective in 
mutated SOD1 leading to elevated levels of superoxide (Harraz et al. 2008). Siglec-E 
knock-down resulted in increased levels of ROS production by microglia. Hence, a 
Siglec-E knock-out might enhance the disease course by additional superoxide 
release. Siglec-E under a constitutively higher expressed promoter specific for 
microglia like iba1 might thus be beneficial for the disease course. A similar 
experimental setup is conceivable in a mouse model of PD or AD as ROS production 
is known to play a detrimental role in the progression of these diseases. The ROS 
released by microglia is harmful for the surrounding neurons and thereby accelerates 
the disease course of PD and AD (Shimohama et al. 2000; Wu et al. 2003). A mouse 
model overexpressing Siglec-E in microglia might be beneficial as it might have 
decreased ROS production and therefore less neurotoxicity. 
The process of phagocytosis is essential for a healthy brain. In the study at hand 
Siglec-E was demonstrated to influence the phagocytosis rate of microglia, 
depending on the expression status of Siglec-E on the microglial surface. AD is one 
of the most prominent neurodegenerative diseases where microglial phagocytosis is 
needed to clear amyloid plaques (Nicoll et al. 2006). Therefore, a mouse model of 
AD could be used to study whether Siglec-E knock-out or overexpression of Siglec-E 
leads to alterations in the plaque load in the brain. The human orthologue Siglec-9 
was shown to be expressed on macrophages and an effect of Siglec-E in AD might 
provide indication of a possible involvement of Siglec-9 in AD as well (Ando et al. 
2008). 
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Concluding, Siglec-E is a modulator of the microglial immune response concerning 
the release of proinflammatory cytokines like IL-1 and TNF-, phagocytosis of cell 
debris and the production of ROS. With these features, Siglec-E should be an 
interesting topic for further studies in the context of different diseases involving 
neuroinflammation, phagocytosis and superoxide production. Since Siglec-E was 
shown to have neuroprotective properties in a co-culture system with neurons, it 
might be a promising target in the therapy and treatment of neurodegenerative 
diseases like PD or AD. More knowledge on the function of Siglec-E is needed to 
better understand its role in the modulation of the immune response. The outcome of 
studies concerning Siglec-E might be interesting for its human orthologues Siglec-7 
and Siglec-9 as well. 
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5. Summary  
 
The aim of this study was to investigate and understand the function of the receptor 
Siglec-E on microglial cells under neuroinflammatory conditions. So far, no data 
about Siglec-E on microglia are available. Therefore the initial step was to prove the 
transcription and expression of Siglec-E in microglia. Ex vivo, primary microglia as 
well as the microglial line were shown to express Siglec-E. To gain knowledge on the 
function of Siglec-E, lentiviral transductions were performed to obtain microglia lines 
either overexpressing Siglec-E or expressing less (knock-down) Siglec-E and the 
corresponding controls. The modified microglia did not show any changes in surface 
marker expression or cytokine transcription after the transduction procedure. 
As phagocytosis is one of the main features of microglia, the phagocytic behaviour of 
the modified microglia was the first to be analysed. Microglia overexpressing Siglec-E 
had a decreased phagocytosis rate of neural debris whereas microglia with a knock-
down of Siglec-E had an increased phagocytosis rate when compared to the 
corresponding controls. The phagocytosis-associated oxidative burst was relatively 
mild after stimulation with neural debris in microglia overexpressing Siglec-E and was 
more prominent in Siglec-E knock-down microglia being fed with neural debris. 
Quantification of mRNA levels of IL-1, iNOS and TNF- after stimulation with neural 
debris revealed that the Siglec-E overexpressing microglia showed no change in 
cytokine production while Siglec-E knock-down microglia showed a significant 
increase of IL-1 and TNF- production following the stimulation. 
Since neurons display high levels of the Siglec-E ligand sialic acid on their 
glycocalyx, the binding capacity of a Siglec-E:Fc fusion protein to neurons was 
tested. While the Siglec-E fusion proteins bound to neurons, this effect was abolished 
after enzymatic removal of sialic acid from the neuronal cell surface by sialidase. A 
co-culture experiment with primary hippocampal neurons and the different modified 
microglia showed that neurons, which had been cultured with microglia 
overexpressing Siglec-E, had the highest relative neurite length. In contrast, co-
culture of microglia with knock-down of Siglec-E and neurons resulted in the lowest 
relative neurite length. Enzymatic removal of sialic acid on the neuronal glycocalyx 
led to an overall comparable decrease in relative neurite length. When the ROS 
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scavenger trolox was added to the co-culture system, the decrease in relative neurite 
length after knock-down of Siglec-E on microglia was restored to the level of the 
corresponding control.  
In summary, these data show that Siglec-E is a regulatory receptor, which plays a 
role in phagocytosis and the associated oxidative burst. In the co-culture experiments 
the overexpression of Siglec-E on the microglia resulted in a neuroprotective 
phenotype by preventing the removal of neurites. The knock-down approach 
revealed that the ROS scavenger trolox is capable of restoring the detrimental effect 
in the co-culture system. Therefore, the neuroprotective effect of Siglec-E was 
mediated by attenuation of reactive oxygen species release. Thus, Siglec-E might be 
an interesting target in diseases associated with neuroinflammation and 
neurodegeneration.
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